For non-commercial use only
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1, Randomized, Double -Blind, Double -Dummy, Active -and Placebo -Controlled, 
5-Way Crossover Study Evaluating the Abuse Potential of Soticlestat (TAK -935) in Healthy
Adult Nondependent Recreational Drug Users With Central Nervous System Depressant
Experience 
Sponsor: Takeda Development Center Americas, Inc.
95 Hay den Avenue
Lexington, MA 02421 USA
Study Number: TAK -935-1012
IND Number: 133627 EudraCT Number: 2018 -002484 -25
Compound: Soticlestat
Date: 15 March 2023 Version/Amendment 
Number:Amendment 1
Amendment History : 
Date Amendment Number Amendment Type Region
15 March 2023 Amendment 1 Substantial Global
29 August 2022 Initial protocol Not Applicable Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed (e)consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable con duct of the study.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 2of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL1.0 ADMINISTRATIVE INFORMATION
1.1 Contacts
A separate contact informat ion list will be provided in the study manual.
Takeda Development Center–sponsored invest igators will be provided wit h emergency medical 
contact informat ion cards at discharg e or early terminat ion to be carried by  each parti cipant.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion
 3.1and relevant guidelines 
provi ded to the study  site.
The names and contact informat ion for the medical monitor and responsible medical o fficer are in 
the study  contact list.
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 4of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALINVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the investigator’s brochure, 
prescribing information and any  other product inform ation provi ded by the sponsor. I agree to 
conduct thi s study  in accordance wit h the requirements of this protoc ol and also to protect the 
rights, life, dignit y, integri ty, confident iality of personal informat ion, safety , privacy, and 
well-being of study  parti cipants in accordance wit h the fo llowing:
The ethical principles that have their origin in the Declaration o f Helsinki.
International Council for Harmonisat ion, E6(R2) Good Clinical Pract ice: Consolidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion 10.2 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the invest igator ( Appendix B).
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 5of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL1.3 Protocol Amendment 01 Summary of Changes
Protocol Amendment 01 Summary and Rationale:
This sect ion describes the changes in reference to the protocol incorporating Amendment 01. The 
primary  reason for this amendment is to update the number of anticipated participants to be 
enrolled into the qualificat ion phase and ult imately randomized into the treatment phase. The 
numbers of participants anticipated now in qualification and treatment phase are approximately 
140 and 65, respectively .
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affect ing the conduct of the study  are included for clarification and administrative purposes only.
Protocol Amendment 01 
Summary of Changes Since the Last Version of the Approved Protocol
No. Sections Affected by 
ChangeDescription Rationale
1 Section 2.0STUDY 
SUMMARY
Section 13.3
Determination of Sample 
SizeUpdated projected number of 
participants to be enrolled 
(qualification phase) and randomized 
(treatment phase).The total number of participants 
expected to be enrolled and randomized 
has been increased due to a 
higher -than -expected number of early 
terminations.
2 Section 7.5.2 Diet, Fluid, 
and Activity ControlUpdated the language to clarify that 
the study  drug will b e administered 
with water.Note added to clarify water intake for 
dosing is excluded from the fasting 
period before and after dosing.
3 Section 8.1.4 Overdose Additional condition added to 
definition of overdose specific to 
current study.To clarify that because the study is 
blinded, ingestion of additional 
tablets/capsules will be considered an 
overdose. 
4 Section 8.5Unblinding 
ProcedureRem oved the requirement for 
providing emergency unblinding 
envelopes to study site.As the study site pharmacy holds the 
randomization schedule for the study, 
these envelopes were not needed and 
subsequently not provided.
Note: The dispensing pharmacist can 
unblind participant’s treatment 
allocatio n without the envolopes.
5 Section 9.1.4 Vital Sign 
ProcedureChang ed heart rate to pulse rate. To align with schedule of events
6 Table 9.aClinical 
Laborato ry TestsReplaced slash (/) with and/or To clarify that urine drug screen (UDS) 
is applicable to all or any of the 
substances mentioned.
7 Section 9.1.9
Documentation of 
Substance Use Histor yUpdated language to clarify the 
timeframe for site to collect substance 
use history.To resolve uncertainty pertaining to the 
timeframe to collect substance use 
history . 
8 Section 9.1.9
Documentation of 
Substance Use Histor yAdded specific quantities for various 
alcoholic beverages under alcohol 
history .Adding definition of alcohol units to the 
protocol.
For non-commercial use only
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 8of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ........................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 01 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 13
3.0 STUDY REFERENCE INFORMATION ...................................................................... 19
3.1 Study -Related Responsibilit ies................................................................................. 19
3.2 Principal and Coordinat ing Invest igator(s) ............................................................... 19
3.3 List of Abbreviat ions............................................................................................... 20
4.0 INTRODUCTION ......................................................................................................... 22
4.1 Background ............................................................................................................. 22
4.2 Rationale for the Proposed Study ............................................................................. 23
4.3 Benefit/Risk Profile .................................................................................................23
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 24
5.1 Object ives................................................................................................................ 24
5.1.1 Primary Object ive............................................................................................ 24
5.1.2 Secondary  Object ives...................................................................................... 24
5.1.3 .................................................................................... 25
5.2 Estimands ................................................................................................................ 25
5.3 Endpoints ................................................................................................................. 25
5.3.1 Primary Endpo int............................................................................................. 25
5.3.2 Secondary  Endpo ints, PD ................................................................................ 25
5.3.3 Secondary  Endpo int, Safet y............................................................................. 25
5.3.4 Other Safet y Endpo ints.................................................................................... 25
5.3.5 .............................................................................. 25
5.3.6 ................................................................................ 26
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 26
6.1 Study  Design ........................................................................................................... 26
6.2 Justification for Study Design, Dose, and Endpoints ................................................ 29
6.2.1 Dose Rati onale ................................................................................................ 29
6.2.2 Rationale for Act ive Co mparator ..................................................................... 29
6.3 Prem ature Terminat ion or Suspension o f Study  or Study  Site................................... 30
6.3.1 Criteria for Premature Terminat ion or Suspension of the Study ........................ 30
6.3.2 Criteria for Premature Terminat ion or Suspension of Study  Site...................... 30
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 9of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL6.3.3 Procedures f or Prem ature Termination or Suspension of the Study  or the 
Parti cipation of  Study  Site(s) ........................................................................... 31
6.3.4 Durati on of  an Individual Participant’s Study  Partici pation.............................. 31
6.3.5 End of Study /Study  Com pletion Definit ion...................................................... 31
6.4 Posttrial Access ....................................................................................................... 31
7.0 SELECTION AND DISCONTINUATION/WITH DRAWAL OF PARTICIPANTS .....31
7.1 Inclusio n Cri teria..................................................................................................... 31
7.2 Exclusio n Cri teria.................................................................................................... 32
7.3 Qualificat ion Cri teria (Applicab le to Passing Qualificat ion Phase) ........................... 34
7.4 Excluded Medicat ions.............................................................................................. 35
7.5 On-Study  Restricti ons.............................................................................................. 36
7.5.1 Alcoho l and Drug Use ..................................................................................... 36
7.5.2 Diet, Fl uid, and Activit y Control ...................................................................... 36
7.6 Criteria for Di scontinuati on or Wi thdrawal  of a Parti cipant ...................................... 37
7.7 Procedures for Discont inuat ion or Withdrawal o f a Parti cipant ................................ 38
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 38
8.1 Study  Drug and Materials ........................................................................................ 38
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling of Study Drug ........... 38
8.1.2 Storage ................................
............................................................................ 39
8.1.3 Dose and Regimen ........................................................................................... 39
8.1.4 Overdose ......................................................................................................... 40
8.2 Study  Drug Assignment and Dispensing Procedures ................................................ 41
8.2.1 Assignment of Participant Identificat ion Number ............................................. 41
8.2.2 Study  Drug Assignment ................................................................................... 41
8.3 Randomization Code Creation and Storage .............................................................. 41
8.4 Study  Drug Blind Maintenance ................................................................................ 41
8.5 Unblinding Procedure .............................................................................................. 42
8.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 42
9.0 STUDY PLAN .............................................................................................................. 43
9.1 Study  Procedures ..................................................................................................... 43
9.1.1 Informed (e)Consent Procedure ....................................................................... 43
9.1.2 Dem ographics, Medi cal History , and Medicat ion History  Procedure ................ 44
9.1.3 Weight and Height ........................................................................................... 44
9.1.4 Vital Sign Procedure ........................................................................................ 44
9.1.5 ECG Procedure ................................................................................................ 44
9.1.6 Physical Examinat ion Procedure ...................................................................... 45
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 10of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL9.1.7 Procedures for Clinical Laboratory  Samples .................................................... 45
9.1.8 Docum entati on of  Conco mitant Medi cations ................................................... 47
9.1.9 Docum entati on of  Substance Use History ........................................................ 48
9.1.10 Docum entati on of  Concurrent Medi cal Condit ions........................................... 48
9.1.11 Clinical Assessment of Suicidal Ideat ion and Behavior .................................... 48
9.1.12 Contraception and Pregnancy Avo idance Procedure ........................................ 49
9.1.12.1 Male Parti cipants and The ir Female Partners ........................................... 49
9.1.12.2 Female Participants and Their Male Partners ........................................... 49
9.1.12.3 Contraceptive Methods for Female Participants of Childbearing 
Potenti al.................................................................................................. 49
9.1.12.4 General Guidance Wit h Respect to the Avo idance of Pregnancy .............. 50
9.1.13 Pregnancy ........................................................................................................ 50
9.1.14 Docum entati on of  Screen Failure ..................................................................... 51
9.1.15 Docum entati on of  Entry  Into the Qualificat ion Phase ....................................... 51
9.1.16 Docum entati on of  Entry  Into the Treatment Phase ........................................... 52
9.2 Safety Moni toring .................................................................................................... 52
9.2.1 Reporting of Abnormal Liver Function Tests ................................................... 52
9.2.2 Reporting of QTcF Interval Increase ................................................................ 53
9.3 ......................................................................... 53
9.3.1 ..53
9.3.2 ..................................... 53
9.4 PD Assessments ....................................................................................................... 53
9.4.1 Subjective Effects VASs .................................................................................. 54
9.4.2 ....................................................................................... 55
9.5 ................................................................ 56
9.5.1 Screening ......................................................................................................... 56
9.5.2 Qualif ication Phase .......................................................................................... 56
9.5.3 Treatment Phase .............................................................................................. 56
9.5.4 Follow-up (Final Visit or ET) .......................................................................... 57
10.0 ADVERSE EVENTS .................................................................................................... 57
10.1 Definit ions............................................................................................................... 57
10.1.1 PTEs ................................................................................................................ 57
10.1.2 TEAEs ............................................................................................................. 57
10.1.3 Addit ional Po ints to Consider for AEs ............................................................. 57
10.1.4 SAEs ............................................................................................................... 60
10.1.5 Intensit y of AEs............................................................................................... 60
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 11of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL10.1.6Causalit y of AEs.............................................................................................. 60
10.1.7 Relationship to Study  Procedures ..................................................................... 60
10.1.8 Start Date ......................................................................................................... 61
10.1.9 Stop Date ......................................................................................................... 61
10.1.10 Frequency ........................................................................................................ 61
10.1.11 Action Concerning Study  Drug ........................................................................ 61
10.1.12 Outcom e.......................................................................................................... 61
10.2 Procedures ............................................................................................................... 62
10.2.1 Colle ction and Reporti ng of AEs ..................................................................... 62
10.2.1.1 AE Collection Period ............................................................................... 62
10.2.1.2 AE Reporting ........................................................................................... 62
10.2.2 Collect ion and Reporti ng of SAEs ................................................................... 62
10.3 Follow-up of  SAEs .................................................................................................. 63
10.3.1 Safety Reporting to Invest igators, IRBs, and Regulatory  Authori ties................ 63
10.3.2 Reporting of Abnormal Liver -Associ ated Test Resul ts..................................... 63
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 63
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 64
12.1 eCRFs ...................................................................................................................... 64
12.2 Record Retention ..................................................................................................... 64
13.0 STATISTICAL METHODS .......................................................................................... 65
13.1 Statistical and Analyt ical Plans ................................................................................ 65
13.1.1 Analysis Sets ................................................................................................... 65
13.1.2 Analysis of Demographics and Other Baseline Characterist ics......................... 66
13.1.3 PD Analysis ..................................................................................................... 66
13.1.3.1 General Considerations ............................................................................ 66
13.1.3.2 Primary Endpo int..................................................................................... 67
13.1.3.3 Secondary  Endpo ints................................ ............................................... 68
13.1.3.4 ............................................................................. 68
13.1.4 ..................................................................................................... 68
13.1.5 Safety Analysis ................................................................................................ 69
13.2 Interim Analysis ...................................................................................................... 69
13.3 Determinat ion of Sample Size .................................................................................. 69
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 70
14.1 Study  Site Moni toring Visits .................................................................................... 70
14.2 Protocol  Deviat ions.................................................................................................. 70
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 12of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 71
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 71
15.1 IRB Approval .......................................................................................................... 71
15.2 Parti cipant Inform ation, Inform ed (e)Consent, and Participant Authorizat ion........... 72
15.3 Parti cipant Confident iality....................................................................................... 73
15.4 Clinical Trial Disclosures and Public ation................................................................ 74
15.4.1 Publicat ion and Disclosure ............................................................................... 74
15.4.2 Clinical Trial Registration ................................................................................ 74
15.4.3 Clinical Trial Result s Disclosure ...................................................................... 74
15.5 Insurance and Co mpensation for Injury .................................................................... 74
16.0 REFERENCES .............................................................................................................. 75
LIST OF IN -TEXT TABLES
Table 6.a Schemat ic of Study  Design ................................................................................ 28
Table 8.a Treatment Descript ion........................................................................................ 40
Table 9.a Clinical Laboratory  Tests ................................................................................... 46
Table 9.b VAS Descript ions.............................................................................................. 55
Table 9.c ......................................................................................... 56
LIST OF APPENDICES
Appendix A ............................................................................ 76
Appendix BResponsibilit ies o f the Invest igator ..................................................................... 84
Appendix C Elements of the Participant Informed (e)Consent ................................................ 86
Appendix D Trial Management During COVID -19 Pandemic ................................................ 89
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 13of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL2.0 STUDY SUMMARY 
Name of Sponsor(s):
Takeda Development Center Americas, IncCompound:
Soticlestat (TAK -935)
Title of Protocol: A Phase 1, Randomized, Double -Blind, 
Double -Dummy , Active -and Placebo -Controlled, 5-Way 
Crossover Study Evaluating the Abuse Potential of 
Soticlestat (TAK -935) in Healthy Adult Nondependent 
Recreatio nal Drug Users With Central Nervous System 
Depressant E xperience IND No .: 133627 EudraCT No .:
2018-002484 -25
Study Number: TAK -935-1012 Phase: 1
Study Design:
This is a phase 1, randomized, double -blind, double -dummy , active -and placebo -controlled, 5 -way crossover study to 
determine the relative abuse potential of single oral doses of soticlestat compared to single oral doses of 2 mg of 
alprazolam and placebo in healthy adult, nondependent recreational drug users with central nervous system (CNS) 
depressant experience.
Participants who complete the study will be in the study for approximately 11 weeks (including approximately 
5weeks in the qualification and treatment phases). This study includes:
Screening phase of up to 4 weeks. 
Qualification phase (4 days). 
Treatment phase (5 periods with at least a 7-day  washout between each period).
Follow -
up visit occurring 7 days after last treatment phase period and discharge from the clinical research unit 
(CRU).
Screen
ing 
Phase
Randomization to Sequence Q1 and Q2Seque
nceQualification Phase
Randomization to Sequence 1 -10Seque
nceTreatment Phase aFollowup 
Phase
within 28 
days of 
qualificat
ion phaseDay 1 Day 2 Period 
1Period 
2Period 3 Period 4 Period 5 Discharge
Treatments Treatments
Q1 Alprazol
amPlacebo 1 A B E C D ~7 ± 3 days 
after final 
dose given at 
the last 
treatment 
periodQ2 Placebo Alprazol
am2 B C A D E
3 C D B E A
4 D E C A B
5 E A D B C
6 D C E B A
7 E D A C B
8 A E B D C
9 B A C E D
10 C B D A E
a Treatment description –treatment phase.
Treatment A: Soticlestat 300 mg.
Treatment B: Soticlestat 600 mg.
Treatment C: Soticlestat 900 mg.
Treatment D: Alprazolam 2 mg.
Treatment E: Placebo.
Each participant will participate in a screening visit (Visit 1) to deter mine eligibility within 28 days of the first dose in 
the qualification phase. Eligible participants will participate in an inpatient, qualification phase (from Day -1 through 
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 15of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALDose Level(s):
Qualification phase : Alprazolam 2 mg and matching 
placebo.
Treatment phase : Soticlestat 300, 600, 900 mg; alprazolam 2 
mg; and corresponding matching placebo.Route of Administration:
Oral
Duration of Treatment:
Qualficatio n phase : Two days of treatment (single doses of 
alprazolam and placebo).
Treatment phase : Five days o f treatment (single doses of 
soticlestat 300, 600, 900 mg; alprazolam 2 mg; and placebo).Period of Evaluation:
Approximately 11 weeks, which include:
Screening phase -up to 4 weeks. 
Qualification phase -4 days. 
At least 4 -day washout between the quali fication 
phase and the treatment phase.
Treatment phase -5 periods with at least a 7-day 
washout between each period. 
Follow -up visit -occurring 7 days after last 
treatment phase period and discharge from the 
CRU.
Main Criteria for Inclusion:
The participant is 18 to 55 years of age, inclusive, at the screening visit.
The participant is healthy as determined by the investigator. 
Participant is a current CNS depressant user who has used CNS depressants (eg, benzodiazepines, barbiturates, 
zolpidem, eszopiclone, zopiclone, propofol/fospropofol, gamma -hydroxy butyrate) for recreational, 
nontherapeutic reasons at least 10 times in their lifetime and at least once in the 12 weeks before screening. 
Participant also must have recreational experience with a t least 1 other drug class associated with abuse (eg, 
opioids, stimulants, cannabinoids, hallucinogens, dissociatives) at least 10 times in their lifetime.
Main Criteria for Exclusion:
Participant has a self -reported history of drug or alcohol dependence (within the past 1 year, except caffeine or 
nicotine, before the screening visit) and assessed by the investigator at screening visit or has ever participated in a 
treatment program or rehabilitation (lifetime) for alcohol or substance dependence (other th an nicotine or caffeine).
Participant has a positive alcohol breathalyzer or urine drug screen (UDS) for substances of abuse at admission, 
excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS, excluding THC, the participant 
may be rescheduled to repeat the UDS and can only be admitted upon a negative UDS being obtained, excluding THC. 
Positive THC UDS will be permitted at admission as long as the participant is not impaired at admission, in the clinical 
judgment of the investi gator. 
Participants have used any concomitant medications (including prescription and nonprescription medications, herbal 
remedies, or vitamin supplements) within 7 days (or 5 times the t 1/2, if known) before the first study drug 
administration in the qualification phase and throughout the study. Exceptions include:
Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for 
the immediate 3 months before first dosing in the qualification phase.
Oral contr aceptive is allowed if its use is consistent (ie, no change in oral contraceptive) throughout the study.
The participant has any positive response on the Columbia Suicide Severity Rating Scale (C -SSRS) or has a risk of 
suicide according to the investigator ’s judgment based on the assessment of the C -SSRS at screening or baseline or has 
made a suicide attempt in the previous 12 months before dosing in the qualification phase.
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 17of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALa)Similar E maxscores (within a 5 -point difference) for a participant across all treatments (including placebo)
OR
b)Emax (positive control) ≤55
OR
c)Emax(placebo) - E max (positive control) ≥5.
This analysis set will be used for PD analyses.
PD Analy sis: General Considerations:
PD endpoints will only be analyzed or summarized for the treatment phase unless otherwise stated.
For each PD endpoint, the number of participants with nonmissing values, mean, standard error, minimum, first 
quartile (Ql), median, third quartile (Q3) and maximum for each treatment and each paired differe nce among 
treatments will be reported for the treatment phase.
The mean response for each treatment over time will be plotted for the primary and secondary PD endpoints.
PD Analy sis: Primary  Endpoint:
The following hypotheses will be tested for the primary PD endpoint of Drug Liking “at this moment” VAS E max.
1.Validation test of the sensitivity and integrity of the study: Does the positive control (C) produce mean responses 
that show greater abuse potential compared with placebo (P)?
H0: µC- µP≤15 vs H a: µC- µP> 15
where µ Cand µ Pare the mean Drug Liking VAS E maxfor alprazolam and placebo, respectively.
2.Does the test drug (T) produce mean responses that show less abuse potential compared to positive control?
H0: µC- µT≤0 vs H a: µC- µT> 0
where µ Tis mean Drug Liking VAS E maxfor soticlestat. This hypothesis will be tested separately for each soticlestat 
dose. Rejection of each null hypothesis would suggest lower relative abuse potential of soticlestat compared to 
alprazolam. 
3.Does the test drug pr oduce mean responses that show similar abuse potential compared with placebo?
H0: µT- µP≥11 vs H a: µT- µP< 11
This hypothesis will be tested separately for each soticlestat dose. Rejection of each null hypothesis would suggest that 
soticlestat does not produce an abuse -related signal.
All hy potheses for the primary endpoint will be tested at 1 -sided 0.05 level of significance. The hypotheses will be 
tested sequentially in the order listed. Within the second and third hypotheses, testing will be ordered from low dose to 
high dose. No adjustments to p -values will be made. All hypotheses will be evaluated using nominal p -values.
Analy sis of the primary endpoint will be performed on the modified completer analysis set. A linear mixed effects 
model containing treatment, period, sequence, and first -order carryover (if applicable) as fixed effects, and participant 
as random effect, is planned to be used to evaluate the hypotheses for the primary endpoint.
If the variances across treatment groups shows potential heterogeneity, the model will be fitted to allow unequal 
variances across treatment groups. If non -normality of residuals is detected in the model, a paired t-test or sign test will 
be used as appropriate for hypothesis testing. If a potential carryover ef fect is detected then a carryover effect term will 
be included in the mixed effects model. 
PD Analy sis: Secondary Endpoints:
The following hypotheses will be evaluated for key and other secondary endpoints. Comparisons among treatments 
will be evaluated a t 1-sided significance level 0.05 for hypothesis 1 and 2, and 2 -sided significance level 0.10 for 
hypothesis 3.
1.Positive control (alprazolam) (C) versus placebo (P): 
H0: µC- µP≤0 vs H a: µC- µP> 0
2.Positive control (alprazolam) (C) versus each dose of soticlestat (T): 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 18of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALH0: µC-µT≤0 vs H a: µC-µT> 0
3.Each dose of soticlestat (T) versus placebo (P):
H0: μT- μP= 0 vs H a: μT- μP≠ 0
No adjustments to p -values will be made. All hypotheses will be ev aluated using nominal p -values.
Key and other secondary PD endpoints will be analyzed with the same linear mixed effects model or nonparametric 
approaches (as appropriate) as the primary endpoint analysis, using the modified completer analysis set and foll owing 
the same strategy for determining the analysis method.
Safety Analysis
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and characterized as 
pretreatment and treatment -emergent according to the intake of the study drugs. TEAEs will be summarized by 
treatment showing the number and percentage of participants who experienced at least 1 TEAE and the number of 
TEAEs reported. A by -participant adverse event (AE) data listing including reported term, coded term, treatmen t, 
severity , and relationship to treatment will be provided. TEAEs leading to discontinuation and SAEs will be listed 
separately.
Vital signs data will be summarized by study phase and treatment and will be listed by participant. Observed values 
and change s from baseline will be presented.
Physical examination abnormalities, ECG results, clinical laboratory values, and C -SSRS responses will be listed by 
participant.
Sample Size Justification: 
The qualification phase of the study is based on a 2 × 2 crosso ver design with oral doses of alprazolam 2 mg and 
matching placebo. The treatment phase is based on a 5 -treatment, 10 -sequence, 5 -period Williams square crossover 
design with treatments A, B, C, D, and E as defined previously. Approximately 140 participants will be enrolled into 
the qualification phase of the study, randomized equally to the 2 sequences. Approximately 65 qualified participants 
will be randomized equally to the 10 sequences in the treatment phase, with the intent to ensure that at least 39 
participants are in the modified completer analysis set. 
It is estimated that, in the treatment phase, a sample size of 39 participants in the modified completer analysis set will 
provide at least 90% power to test each of the hypotheses for the primary PD endpoint. Power calculations used a 
paired t -
test and assumed a true SD of 23 points for within -participant differences for each planned treatment 
comparison on the Drug Liking VAS E max, a true mean difference of 26 points between alprazolam 2 mg and plac ebo, 
and a true mean difference of 0 points between placebo and each dose of soticlestat. 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 19of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
clinical supplier list in the study manual. The ident ified vendors will perform these act ivities eit her 
in full or in partnership wi th the sponsor.
The study  is being funded by  Takeda. Payments for the conduct of the study  that will be made to 
the study  site (and, if applicable, invest igators and/or other study  staff) will be specified in the 
Clinical Study  Site Agreement(s). All invest igators and sub -invest igators must declare potential 
conflicts of interests to the sponsor. The sponsor will provide a fina ncial disclosure form that must  
be signed by  each invest igator and sub -invest igator before the study starts at their study site; in 
addition, any potential conflicts of interests that are not covered by  this financial  discl osure f orm 
shoul d be discl osed se parately  to the sponsor before the start of the study  at thei r study  site.
All institutional affiliat ions of the invest igator and subinvest igator should be declared on their 
curriculum vitae, which must be provided to sponsor before the start of the study .
3.2 Principal and Coordinating Investigator(s)
The principal invest igator at the single study site has significant knowledge of the study  protocol , 
the study  drug, experti se in the therapeut ic area, and the conduct of clinical research. The 
coordinat ing inves tigator for the study will be required to review and sign the clinical study report 
(CSR) and by do ing so agrees that it accurately describes the results of the study .
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 20of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL3.3 List of Abbreviations
24HC 24S-hydroxy cholesterol
AE adverse event
ALT alanine aminotr ansferase
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC ∞ area under the concentration -time cuve from time 0 to infinity
AUC last area under the concentration -time curve from time 0 to last quantifiable concentration
BID twice daily
Bs baseline
CDER Center for Drug Evaluation and Research
CH24H cholesterol -24 hy droxy lase 
Cmax maximum observed concentration
Cmax,u unbound C maxconcentration
CNS central nervous system
COVID -19 coronavarius disease 2019
CRU clinical research unit
CSA Controlled Substances Act
CSR clinical study report
C-SSRS Columbia Suicide Severity Rating Scale
CYP cytochrome P -450
DEE developmental epileptic encephalopathy
DS Dravet syndrome
DSM -IV-TR Diagnostic and Statistical Manual of Mental Disorders -IV text revision
ECG electrocardiogram
eCOA electronic clinical outcome assessment
(e)consent electronic or written consent
eCRF electronic case report form
EDC electronic data capture
Emax maximum effect
ET early  termination
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamyl transferase
hCG human chorionic gonadotropin
IB investigator’s brochure
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 21of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALICF informed consent form
ICH International Council for Harmonisation
INR internatio nal no rmalized ratio
IRB institutional review board
LGS Lennox -Gastaut syndrome
MedDRA Medical Dictionary for Regulatory Activities
MRD multiple -rising dose
MRHD maximum recommended human dose
NMDA N-methy l-D-aspartate
PD pharmacodynamic(s)
P-Gp P-glycoprotein
PK pharmacokinetic(s)
PTE pretreatment events
QD once daily
QTcF Fridericia -corrected QT interval
rSDV remote source data verification
SAE serious adverse event
SRD single -rising dose
SUSAR suspected unexpected serious adverse reaction
t1/2 terminal disposition phase half -life
TEAE treatment -emergent adverse event
THC tetrahy drocannabinol
tmax time of first occurrence of C max
UDS urine drug screen
UGT uridine 5' -diphospho -glucuro nosyltransferase
ULN upper limit of normal
US United States
VAS visual analogue scale
WHO World Health Organization
WOCBP women of childbearing potential 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 22of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
Soticlestat is being developed for the treatment of seizures in patients wit h Dravet syndro me (DS) 
and Lennox -Gastaut syndrom e (LGS). 
Soticlestat i s a potent inhibit or of  chol esterol -24 hydroxylase (CH24H) in the brain. Alt hough the 
exact therapeutic mechanisms o f soticlestat still remain to be fully  understood, pharm acological  
modulat ion of CH24H can potentially alter the function of N-methyl -D-aspartate (NMDA) 
receptors because 24S -hydroxycho lesterol (24HC), the metabolic product of CH24H react ion, is 
known as an endogenous modulator of the NMDA (Paul et al. 2013 )receptors. Therefore, 
soticlestat can be considered an indirect NMDA modulato r, which is mediated by reduct ion of 
24HC. 
Nonclinical studies have demo nstrated that soticlestat modulates glutamatergic signaling and 
significant ly reduces spontaneous seizure in murine models. The phase 2 clinical study 
TAK -935- 2002 (ELEKTRA) showed ef ficacy of soticlestat in participants with DS or LGS who 
had seizures that were intractable to current antiseizure medicat ions. 
Soticlestat i s rapi dly absorbed following oral administration with a median t ime to maximum 
plasma concentration of 0.5 to 0.75 hours (oral tablets; TAK -
935-1005 and TAK -935-1004) and a 
mean terminal disposit ion phase half -life (t 1/2) ranging fro m 2.6 to 8.7 hours (oral tablets). 
Exposure to soticlestat increased in a greater than dose- proporti onal manner over the single -dose 
range of 200 to 1200 m g (oral  tablets; TAK -935- 1004) and 15 to 1350 mg (oral so lution; 
TAK -
935-101). 
The posi tron emissio n tom ography  imaging data showed that the enzyme occupancy increased 
with increasing dose and plateaued at approximately 93% at 2 hours with 200 mg single dose. The 
maximum enzyme occupancy of approximately 96% at 2 hours was observed at the 600 mg single 
dose. Al though soti clestat rapi dly engages wi th the CH24H target, maximum reduction of 24HC 
levels (ie, the pharmaco logical mediator of soticlestat’s effects) was observed at approximately 16 
hours postdose after single 50, 200, and 600 mg doses and at approximately  48hours postdose 
after single 900 and 1350 mg doses (TAK -
935-101 CSR).
In addit ion, although soti clestat has a relatively s hort pl asma eliminat ion t1/2, the 
pharmacodynamic (PD) effect (ie, reduction of 24HC levels) returned slowly to baseline at 
96hours postdose fo llowing single doses (TAK -935-101 CSR). Average change from baseline 
24HC during 12 hours at steady -state were s imulated at increasing twice daily (BID) doses based 
on a populat ion pharmacokinetics (PK) and 24HC model of pooled data from phase 1 and phase 2 
studi es. Simulations with 100, 200, and 300 mg BID indicate that 24HC levels returned to baseline 
within 7 day s after treatm ent stop (Population PK/24HC Memo dated 16 December 2021).
Since soticlestat is a central nervous system (CNS) –active new mo lecular ent ity, Takeda has 
conducted the agreed nonclinical abuse/dependence evaluat ion of the compound, as per United
States (US) Food and Drug Administration (FDA) guidelines. The nonclinical evaluat ion of abuse 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 23of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALpotenti al showed that soti clestat di d not have any significant 2 -dimenisonal structural similarit ies 
to Schedule I to V compounds listed in the US Controlled Su bstances Act or bind to known 
abuse -related pharmacol ogic targets at clinicaly  relevant concentrati ons (Investigator’s Brochure 
[IB] Edit ion7).
In vivo, soticlestat was not found to produce physical dependence in a rat model o f chronic 
soticlestat dosing and then withdrawal at plasma values that were up to approximately 20 -fold the 
maximum observed concentration (C max) at the m aximum  recommended human dose (MRHD) of 
300 m g BID (Study  8478301). 
In addit ion, soticlestat did not have reinforcing properties i n an intravenous (IV) 
self-administrati on m odel in rats at plasma levels of up to 1.4 -fold the MRHD (Study  8478298) 
and did not generalize to the interoceptive cue produced by ketamine in rats at plasma 
concentrations of up to approximately 7.4 -fold the C maxat the MRHD (Study  8478299). 
Combining studies of phase 1 and the placebo -controlled parts of phase 2 studies, the incidence of 
abuse related, treatment -emergent adverse events (TEAEs) was 17.9% for soticlestat versus 9.6% 
for placebo and consisted mos tly of dizziness and somno lence. Focusing on abuse -related TEAEs 
that em erged on Day 1 of treatm ent, the time most relevant to human abuse, the incidence of 
abuse -related TEAEs was 4.7% for participants on soticlestat versus 1.8% for participants on 
placebo (CSRs TAK -935- 101, TAK - 935 -1002, TAK -935- 1004, TAK - 935-2008 [part A], 
TAK -
935-2001 [part 1] and TAK - 935-2002). 
There were 3 reports of euphoric mood by part icipants receiving soticlestat. Although there were 2 
cases o f euphori c mood wi thin 1 to 2 hours of soticlestat dosing, evaluat ion of PD parameters for 
these parti cipants di d not show a marked effect on 24HC concentrations at this time, indicat ing 
that the effects were unlikely related to soticlestat .
4.2 Rationale for the Proposed Study
As part of the co mprehensive assessment of the relative abuse potential o f soticlestat, which 
includes nonclinical and clinical assessments, and in accordance with guidelines provided by FDA 
and to m eet the requi rement for regul atory  filing and registration, this study  will be conducted to 
provi de addi tional informat ion on the relat ive abuse potential o f soticlestat in healt hy adult 
nondependent recreational drug users with CNS depressant experience.
4.3 Benefit/Risk Profile 
In the phase 1b/2a and phase 2 studies co mpleted to date, the safet y and tol erabilit y data indicate 
that soti clestat was generally safe and well tolerated in participants with developmental epilept ic 
encephalopathies (DEEs) at doses up to 300 mg BID (weight -based dosing for <60 kg) with init ial 
dose up -titration.
To date, Takeda has completed a total of 10 clinical studies including phase 1 single -rising 
dose (SRD) and mult iple-rising dose (MRD) studies in healthy part icipants and phase 2 studies 
in DEE and pat ients with com plex regi onal pain syndrom e (CRPS) . Overall, soticlestat was 
safe and well tolerated, and there were no observed dose responses for TEAEs in 2 SRD 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 24of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALstudi es where the healt hy part icipants were dosed with up to 1350 mg (TAK -935-101) and 
1200 mg (Part 1 of TAK -935- 1004). 
In the TAK -
935-1002 M RD study, where dose up -titration/optimizat ion was not implemented, 
soticlestat at 300 m g BID and 600 m g once daily  (QD) di d not appear to be well tolerated by  
healt hy participants due to the emergence o f multiple neurol ogical and psychiatri c events 
(refer ence TAK -935- 1002, CSR). These events/TEAEs were all mild except for 1 case of acute 
psychosi s (severe), inso mnia (severe), and distractibilit y (moderate) reported by  the same 
participant. The condit ions of the TEAEs were reversible, and all participants r ecovered. There 
were no serious adverse events (SAEs). No clear dose -response relationship was observed for 
any specific TEAE across all dose cohorts.
All subsequent repeated -dose studies implemented dose up -titration/optimizat ion to the target 
dose l evels of up to 300 m g BID. No individual or populat ion dose -response for safet y events 
have been observed during the dose up -titration/optimizat ion and maintenance periods. 
Soticlestat has been well tolerated up to 300 mg BID with dose up -titration/optimizat ion
without emergence of any  new safet y issues to date.
This study  eval uates 3 different single dose levels, including 300, 600, and 900 mg, all of which 
were generally safe and well tolerated in phase 1 studies. Further, single doses higher than 900 mg 
were also safe and well tolerated in phase 1 studies, as described above.
This i s an inpat ient study , and the participants will be closely mo nitored for the emergence of any 
adverse events (AEs), which will be managed at the earliest as required. 
More informat ion about the known and expected benefits and risks of soticlestat may be found in 
the current edition o f the IB. In thi s heal thy adult nondependent recreati onal drug user wi th CNS 
depressant experience populat ion, no beneficia l effects are expected; howev er, this study will help 
evaluate the relative abuse potential of 3 different single dose levels o f soticlestat com pared wi th 
placebo and posi tive control alprazo la
m in humans and add further data to the profile of overall 
benefit -risk in DS and LGS. 
5.0 STUDY OBJECTIVES AND END POINTS
5.1 Objectives
5.1.1 Primary Objective
To evaluate the relative abuse potential o f soticlestat compared with placebo and alprazo lam under 
fasted condit ions in healt hy adult nondependent recreational drug users with CNS depressant 
experienc e.
5.1.2 Secondary Objectives
To evaluate addit ional PD effects and safet y of soticlestat com pared wi th placebo and al prazolam 
under fasted condit ions in healthy adult nondependent recreati onal drug users wi th CNS 
depressant experience.
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 28of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALTable 6.a Schematic of Study Design
Screening 
Phase
Randomization to Sequence Q1 and Q2Seque
nceQualification Phase
Randomization to Sequence 1 -10Seque
nce bTreatment PhaseaFollow -up 
Phase
within 28 
days of 
qualification 
phaseDay 1 Day 2 Period 1 Period 2 Period 3 Period 4 Period 5 Discharge
Treatment Treatment
~7 ± 3 day s 
after final 
dose given 
at the last 
treatment 
periodQ1 Alprazolam Placebo 1 A B E C D
Q2 Placebo Alprazolam 2 B C A D E
3 C D B E A
4 D E C A B
5 E A D B C
6 D C E B A
7 E D A C B
8 A E B D C
9 B A C E D
10 C B D A E
a Treatment description –treatment phase.
Treatment A: Soticlestat 300 mg.
Treatment B: Soticlestat 600 mg.
Treatment C: Soticlestat 900 mg.
Treatment D: Alprazolam 2 mg.
Treatment E: Placebo.
bSequences are based on a Williams design (Williams 1949 )(ie, uniform within sequences, unform within periods, and balanced with respect to first -order 
carry over effects). The specific sequences used here were calculated using the crossdes package (Package ‘crossdes,’ Construc tion of crossover d esigns, April, 
2022) in R (R Core Team [2021]. R: A language and environment for statistical computing. R Foundation for Statistical Computi ng, Vienna, Austria).
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 29of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL6.2 Justification for Study Design, Dose, and Endpoints
6.2.1 Dose Rationale
This study  is undertaken to assess the relat ive human abuse potential o f a single dose of soticlestat 
at the highest proposed therapeutic level o f 300 mg administered BID and supratherapeut ic dose 
levels (600 and 900 mg). 
Three dose levels are chosen to determine dose response, if any. A supratherapeut ic dose of 
600and 900 mg will represent an adequate 2 -and 3 -fold difference fro m the highest proposed 
therapeuti c dose l evel, respectively (FDA, Guidance for Industry  Assessment of Abuse Potential 
of Drugs, January , 2017). 
The supratherapeutic dose levels o f 600 and 900 mg also present >2- and >3 -fold difference from 
the C maxand area under the concentration -time curve (AUC) from time 0 to the last quantifiable 
concentration (AUC last) and fro m time 0 to infinit y (AUC ∞) than the highest proposed therapeutic 
dose l evel of 300 m g, respect ively, as exposure of soticle stat generally increased more than dose 
proporti onally from  200 to 1200 m g (oral  tablets; TAK -935- 1004 CSR). In the clinical setting 
soticlestat is administered as BID doses and no clinically meaningful accumulat ions were 
observed fo llowing mul tiple BID do ses (accumulatio n rati o 1.05; TAK -
935-1004 CSR).
In addit ion, measured CH24H enzyme occupancy increased with increasing dose and plateaued at 
200 mg single dose (approximately 93% at 2 hours; TAK -
935-1003 CSR). The maximum enzyme 
occupancy  was achieved at a 600 mg single dose, the highest dose tested in the study 
(approximately 96% at 2 hours). 
Soticlestat was safe and well tolerated when administered as a single dose up to 1350 mg 
(TAK -
935-101 CSR). In vitro screening of soticlestat against a panel o f more than 100 known 
molecular targets such as receptors, ion channels and enzymes revealed no relevant off -target 
activit y at tested concentrations (3735 ng/mL [reports TAK -
935-10077, 100054231 and 
OTI-
20-21]) higher than the unbound C maxconcentrati on (C max,u) associated with a single 1350 mg 
dose [C max7953 ng/mL (TAK -
935-101 CSR); C max,u2338 ng/mL assumes 70.6% bound 
(TAK -
935-1005)]. 
6.2.2 Rationale for Active Comparator
Alprazo la
m 2 mg has been selected as the active comparator based on the fo llowing:
Accor ding to FDA guidance (US Department of Health and Human Services, FDA, Center for 
Drug Eval uation and Research (CDER): Assessment of Abuse Potential o f Drugs, January  
2017), i deally , “the posi tive control should be an FDA -approved drug that is 
pharmaco logically similar to the test drug and scheduled under the [Controlled Substances Act] 
CSA.”
Soticlestat i s a novel co mpound that is not pharmacologically similar to any exist ing drugs of 
abuse. Alt hough soti clestat m ay exert i ts pharm acological act ion through indirect effects on 
NMDA receptors, it did not generalize to ketamine in a rat drug discriminat ion study , 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 30of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALindicat ing that it does not share subject ive similarities to ketamine, a prototypic NMDA 
receptor antagonist. For a compound with novel mechanism o f action, such as soticlestat, FDA 
recommended an appropriate posit ive control of a depressant listed under schedule IV of the 
CSA (eg, a benzodiazepine). 
Soticlestat produced no abuse -like behavioral effects in rats or dogs, eg, excitation, 
hyperact ivity, stereoty py, somnol ence, sedati on, or “wetdog” shakes, at doses ≤500 m g/kg 
(juvenile rats), ≤300 mg/kg (adult rats) or ≤30 mg/kg (dogs). In humans, acute a nd chronic 
administration of soticlestat in patients and healt hy participants did not produce effects 
(ie,sedative, stimulant, mood- elevating, or hallucinogenic effects) consistent with those of 
abused drugs, even when administered at supratherapeutic dos es. 
Overall, the data with soticlestat do not suggest any  parti cular class of drugs of abuse as an 
ideal posit ive control; therefore, a benzodiazepine has been selected as a positive control, as 
these have some similarit ies in therapeut ic effects to sotic lestat (ie, ant iconvulsant effects) and 
a similar potential general indicat ion (ie, treatm ent of seizure disorders). 
Benzodi azepines, and more specifically  alprazolam , has been used, as posi tive control, in a 
number of prior human abuse potential studies of anti-epileptic drugs with novel 
pharmaco logy (Levy -Cooperm an et al . 2016 ; Schoedel et al. 2017 ; Schoedel  et al . 2018a ; 
Schoedel et al. 2018b ).
Because of the flat dose -response observed with benzodiazepines on subjective measures such 
as Drug Liking (Levy -Cooperm an et al. 2016 ), only 1 dose will be included in the current study. 
The 2 m g dose of alprazo lam was selected because it has been used in previous huma n abuse 
potenti al studi es ment ioned above and is not expected to produce the sedat ion often observed 
with the higher 3 mg dose, which may interfere wit h the collect ion of subjective PD measures. 
6.3 Premature Termination or Suspension of Study or Study Site
6.3.1 Criteria for Premature Termination or Suspension of the Study
The study  will be co mpleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early  terminat ion (ET) of the study .
New informat ion or other evaluation regarding the safet y or PD of the study drug that indicates 
a change in the known risk/benefit profile for the compound, such that the risk/benefit profile 
is no longer acceptable for participants participat ing in the study .
Significant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study  objectives or compromises participant safet y.
6.3.2 Criteria for Premature Termination or Suspension of Study Site
A study  site may be terminated prem aturely or suspended if the study  site (including the 
investigator) is found in significant vio lation o f GCP, protocol, or contractual agreement, is unable 
to ensure adequate performance of the study , or as otherwi se permitted by  the contractual  
agreem ent.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 31of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL6.3.3 Procedures for Prem ature Termination or Suspension of the Study or the 
Participation of Study Site(s)
In the event that the sponsor, inst itutional review board (IRB), or regulatory  authori ty elects to 
terminate or suspend the study  or the parti cipat ion of a study  site, a stu dy-specific procedure for 
ET or suspensio n will be provided by the sponsor; the procedure will be fo llowed by the study site 
during the course of terminat ion or study  suspension.
6.3.4 Duration of an Individual Participant’s Study Participation
Parti cipants who complete the study *will be in the study for approximately 11 weeks (including 
approximately  5 weeks (in the qualification and treatment phases).
This study  includes: 
Screening phase of up to 4 weeks. 
Qualificat ion phase (4 day s). 
Treatment phase (5 per iods wi th at least a 7 day  washout between each period).†
Follow-up visit occurring 7 days after last treatm ent phase period and discharge fro m the CRU.
6.3.5 End of Study/Study Completion Definition
The end o f the study  for an individual part icipant is defined as the l ast protocol -specified contact 
with that parti cipant. The overall end of the study  is defined as the last protocol -specified contact 
with the l ast parti cipant ongoing in the study .
6.4 Posttrial Access
Not applicable in this healt hy part icipant study .
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF PARTICIPANTS
All entry  criteria, including test results, need to be confirmed before entry  into the study .
7.1 Inclusion Criteria
Parti cipant eligibilit y is determined according to the fo llowing criteria before entry into the study :
1.The parti cipant is willing and able to understand and fully  com ply wi th study  procedures and 
requi rements (including digital tools and applicat ions), in the opinio n of the investigator.
2.The parti cipant has provided written, signed, and dat ed informed consent and any required 
privacy  authori zation before the init iation of any  study  procedures.
3.The parti cipant is 18 to 55 y ears of age, inclusive, at the screening visit.
                                               
*The site may extend the participant’s participation by extending the duration between qualification phase and 
Treatment phase to maximize site efficiency/scheduling.
†At minimum, there will be a 4- day washout between the qualification phase and the treat ment phase.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 32of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL4.The participant is healt hy as determined by the investigator. Healthy is defined as no clinically 
relevant abnormalit ies ident ified by a detailed medical history, complete physical examinat ion, 
vital signs, 12 -lead ECG, and clinical laboratory tests.
5.Parti cipant i s a current CNS depressant user who has used CNS depressants (eg,
benzodiazepines, barbiturates, zolpidem, eszopiclo ne, zopiclo ne, propofo l/fospropofo l, 
gamma- hydroxybut yrate) for recreational, nontherapeutic reasons at least 10 times in their 
lifetime and at least once in the 12 weeks before screening. Participant must also have 
recreati onal experience wi th at least 1 other drug class associated with abuse (eg, opio ids, 
stimulants, cannabino ids, hallucinogens, dissociat ives) at least 10 times in their lifet ime.
6.The parti cipant has a body  mass index of 18.5 to 35.0 kg/m2, inclusive, and a minimum body  
weight of  50.0 kg at screening.
7.Female participants of childbearing potential (defined in Sect ion 9.1.12.2 ) must have a 
negat ive pregnancy test at screening and agree to use an effect ive or highly effective method of 
birth control, as listed in Sect ion 9.1.12.3 , during the study  and f or 32 day s following the l ast 
dose of study  drug.
7.2 Exclusion Criteria
Any participant who meets any  of the f ollowing criteria will not qualify for entry  into the study : 
1.The parti cipant has a self- reported history  of drug or al coho l depen dence (wi thin the past 
1year, except caffeine or nicotine, before the screening visit) as defined by the Diagnostic and 
Statistical Manual o f Mental  Disorders -IV text revisio n (DSM -IV-TR; [American Psychiatric 
Associ ation, 2000]) and assessed by the inves tigator at screening visit or has ever participated 
in a treatm ent program  or rehabilitat ion (lifet ime) for alcoho l or substance dependence (other 
than nicoti ne or caffeine).
2.The participant has a posi tive al coho l breathalyzer or urine drug screen (UDS) fo r substances 
of abuse at admissio n, excluding tetrahy drocannabino l (THC). If a parti cipant presents with a 
positive UDS, excluding THC, the participant may be rescheduled to repeat the UDS and can 
only be admi tted upon a negat ive UDS being obtained, exclud ing THC. Posit ive THC UDS 
will be permitted at admissio n as lo ng as the participant is not impaired at admissio n, in the 
clinical judgment of the invest igator. 
3.The parti cipant is a heavy smoker or user of other types of nicotine products (>20 cigarettes 
equivalent per day ).
4.The parti cipant is unable to abstain from smoking for at least 2 hours before and at least 
8hours after dosing. 
5.The parti cipant consum es excessive am ounts, defined as greater than 4 servings (1 serving is 
approximately  equivalent to 120 m g of caffeine) of coffee, tea, cola, energy  drinks, or other 
caffeinated beverages per day .
6.The parti cipant has used any  concomi tant m edicat ions (including prescript ion and 
nonprescript ion medications, herbal  remedies, or vi tamin supplements) wi thin 1 4 days (or 5 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 33of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALtimes the t 1/2, if known) before the first study drug administration in the qualificat ion phase and 
throughout the study . 
Except ions include:
–Thyroid horm one replacement medicat ion may be permitted if the participant has been on 
the sam e stab le dose for the immediate 3 months before first dosing in the qualficat ion 
phase.
–Oral contraceptive i s allowed if i ts use is consistent (ie, no change in oral contraceptives) 
throughout the study
7.The parti cipant has used any  drug known to be a significant inducer of cytochro me P -450 
(CYP) 3A, CYP2C19, uridine 5'- diphospho -glucuronosyltransferase (UGT) 1A9 or UGT2B4 
enzymes, and/or P -glycoprotein (P -gp), including St. John’s wort, within 28 days before the 
first dose in the qualificat ion phase. (Appropriate sources [eg, Flockhart Table] will be 
consulted to confirm lack o f PK-PD interacti on wi th study  drug.)
8.The parti cipant has received: 
–An invest igational drug within 5 × the known eliminat ion t1/2, or, if the t 1/2is unknown, 
within 30 days of first antici pated study  drug administrati on in the qualificat ion phase. 
–An invest igational biologic product wi thin 90 days before the first anticipated study  drug 
administration in the qualificat ion phase.
9.The parti cipant took part in a previous soticlestat clinical study .
10.The parti cipant has a history  or current presence of any  clinically significant medical 
condi tions, which in the opinio n of the Invest igator would jeopardize the safet y of the 
participant or the validit y of the study  resul ts (eg, any  major cardi ovascular, pulm onary, 
hepat ic, renal, hematologic, gastrointest inal, endocrine, ophthalmo logic, immuno logic, 
derm atologic, neurol ogic, oncol ogic, m usculo skeletal , psychiatri c disease [including an 
established diagnosis o f an underlying psychotic illness], or c linical assessment abnormalit y 
[as found in physical examinat ion, medical history, 12 -lead ECG, vital signs, or clinical 
laboratory  values]).
11.The parti cipant has a history  or presence of any of the fo llowing specific ECG abnormalit ies: 
–Established QT prol ongat ion.
–Atrial fibrillat ion.
–Long QT syndrome.
–Torsades de pointes.
–Brady arrhy thmia.
–Unco mpensated heart failure.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 34of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL–Any 12 -lead ECG with repeated demonstration of Fridericia -corrected QT interval (QTcF) 
≥470 m sec in female part icipants, ≥450 msec in male p artici pants, and/or a QRS interval 
≥120 m sec at screening.
12.The parti cipant has a family  history  (anamnesis or first degree relative with history ) of 
unexplained sudden death or long QT syndrome. 
13.The parti cipant has evidence of clinically  significant hepat ic or renal impairment including 
(but not limited to) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2× 
the upper limit of normal (ULN), or clinically significant renal impairment as shown by 
estimated creatinine clearance < 80 mL/min (using the Cockcroft -Gaul t equati on).
14.The parti cipant has a history  of severe allergic reacti on (including anaphylaxis) to any  food, 
medicat ions, or bee sting, or a history  of previ ous status asthmaticus.
15.The parti cipant has a history  of allergy  or hy perse nsitivity to alprazo lam or rel ated drugs.
16.The parti cipant tests posit ive for hepat itis B, hepat itis C, or HIV at the screening visit.
17.The parti cipant has had any significant illness, of any  nature, including coronavirus disease 
2019 (COVID -19) –related fev er and symptom s, requi ring hospi talizati on, emergency  
treatm ent, or i solation (communit y mandated quarant ine) within 4 weeks before screening or 
during the study  and as determined by  the invest igator. 
18.The participant has donated or lost more than 500 mL o f who le blood within 30 days preceding 
anticipated entry  into the treatment phase.
19.The parti cipant is current ly pregnant or breastfeeding.
20.The parti cipant has any  posi tive response on the C -SSRS or has a risk of suicide according to 
the invest
igator’s judg ment based on the assessment of the C -SSRS or has made a suicide 
attem pt in the previous 12 months.
21.The parti cipant is considered unsuitable or unlikely  to com ply with the study  protocol  for any  
reason by the investigator.
7.3 Qualification Criteria (Applicable to Passing Qualification Phase)
Parti cipants will be required to meet all o f the follo wing qualificat ion criteria to be eligible to enter 
the treatment phase:
1.The participant continues to meet all o f the inclusio n criteria and none o f the exclu sion criteria 
above.
2.The parti cipant sati sfactorily  com pletes the qualification phase.
3.On the assessment of drug liking (“at the mo ment” Drug Liking VAS): 
–The parti cipant’s E maxon “at the m oment” Drug Liking VAS in response to alprazo lam is 
numerically  ≥15 points higher than that of placebo, and the participant has an E maxof ≥65 
points wi th alprazo lam.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 35of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL–The parti cipant has an acceptable placebo response based on the Drug Liking VAS, 
defined as a E maxbetween 40 and 60 points (ie, a score considered neutra l on the scale, 
meaning neit her like nor dislike), inclusive.
–The parti cipant has acceptable overall responses to alprazolam and placebo on the 
subjective measures, as judged by the invest igator or designee.
4.The safet y data available fo llowing study  drug a dministrati on suggest that the participant will 
be able to tolerate the alprazo lam 2 m g dose pl anned for the treatment phase, as judged by the 
investigator, including no missing PD assessments within 4 hours of drug administration.
5.The participant's genera l behavior suggests that the participant could successfully co mplete the 
study , as judged by the investigator.
7.4 Excluded Medications
All nonstudy  medicati ons, including prescript ion, over -the-counter, herbal therapies, or vitamin 
supplements used by  the par ticipant will  be documented for the 30 day s before screening and 
throughout the study. The investigator will determine if the prior/concomitant medicat ion(s) affect 
the participant’s eligibilit y to parti cipate or continue to participate in the study . The f ollowing 
restri ctions on concomitant medicat ions will be in place during the study : 
The use of prescription drugs (except hormonal contraceptives and hormone replacement 
therapy ), vitamins, or mineral supplements and natural health products (eg, herbal re medies) 
will be restricted for at least 14 days (or 5 times the t 1/2of the drug, if known) before first study 
drug administration in the qualificat ion phase and throughout the study  (excepti ons include 
alprazo lam administered as posit ive control and thyro id hormone replacement medicat ion as 
long as the participant has been on the same stable dose for the immediate 3 months before the 
first study drug administrati on in the qualificat ion phase).
The use of over -the-counter medicat ions (except acetaminophen o r ibuprofen) will be 
restri cted for at l east 14 days (or 5 -times the t 1/2of the drug, if known) before first study  drug 
administration in the qualificat ion phase and throughout the study .
The use of invest igational drugs will be restricted for 5 × the kno wn t 1/2or, if the t 1/2is 
unknown, for 30 days, before the first anticipated study drug administration in the qualificat ion 
phase and throughout the study . 
The use of invest igational biologic products will be restricted for 90 day s, before the first 
anticipated study  drug administrati on in the qualification phase and throughout the study .
Any drugs known to be significant inducers of CYP3A, CYP2C19, UGT1A9, or UGT2B4 
enzymes and/or P -gp, including St. John’s wort, will be restricted within 28 days before the 
first study drug administration in the qualificat ion phase and throughout the study. Appropriate 
sources (eg, Flockhart Table) will be consulted to confirm lack of PK/PD interaction with 
study  drug.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 36of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL7.5 On-Study Restrictions
Parti cipants will enter the stu dy site the day before dosing (Day -1) of  the qualificat ion phase.
In addit ion to the inclusio n/exclusio n criteria, the parti cipant m ust agree to abi de by  the study  
restri ctions listed in Sect ions 7.5.1 and 7.5.2 .
7.5.1 Alcohol and Drug Use
Parti cipants will be asked to abstain from alcohol for 24 hours before each study  visit. If a 
participant presents with a posit ive breath alcoho l test at any  visit after the screening visit, the 
participant m ay be rescheduled to repeat the breathalyzer test at the respective admissio n visit 
and can only be admitted upon a negative result being obtain ed.
Parti cipants will be asked to abstain from recreat ional drug use/experience throughout the 
study , from screening unt il after the fo llow-up visit or ET. Abst inence will be confirmed via 
UDS (at screening, at admissio n [Day  
-1] to the qualificat ion phase and at check -in for the 
treatm ent phase. (Note: If participant is released at investigator discret ion from the clinic 
during the treatment phase [during washout], participant will be checked in again upon 
readmittance to the clinic for the next treatment period.)
–If a participant presents with a posit ive UDS at screening, invest igator may determine if the 
screening visit may  cont inue that day  or if it should be continued another day . In these 
cases, invest igator may conduct a screening visit over mult iple days. In these cases, ] at 
investigator discret ion, screening procedures may be repeated.
–If a participant presents with a posit ive UDS (excluding THC) at admissio n to the 
qualificat ion phase, the participant will not be admitted but may, at the discret ionof the 
investigator, repeat the UDS at a later date and be admitted to the qualificat ion phase upon 
a negat ive UDS being obtained. (Note: In case of discharge between qualificat ion phase 
and treatment phase same condit ions apply.)
–Positive THC UDS will be permitted at admissio n to the qualificat ion phase as long as the 
participant is not impaired at admissio n, in the clinical judgment of the invest igator. 
Parti cipants will be advised that no THC use is permitted during the inpat ient qualificat ion 
or treatm ent phases.
7.5.2 Diet, Fluid, and Activity Control
Parti cipants will be requi red to fast (abstain from food) for at least 8 hours before dosing and 
for at least 4 hours postdose on the day of dosing. Water will be permitted ad libitum except for 
approximately  1hour before dosing and for approximately 1 hour postdose (except water 
provi ded with each dosing). Note: Study drug will be administered with approximately 240 ml 
of water. If addit ional water is needed for a participant to ingest the study drug, up to 50 ml of 
additional water m ay be provi ded.
Parti cipants will be asked to abstain from strenuous physical act ivity for 48 hours before 
admissio n, and during inpatient stays at the study  site.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 37of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALParti cipants will be asked to abstain fro m the fo llowing foods from 1 week before admissio n to 
the qualificat ion phase unt il after the fo llow-up visi t or ET: 
–Grapefruit, pomegranate, pomelo, and star fruit and their juices/products. 
–Poppy  seeds and Seville oranges and foods con taining them (eg, orange marmalade). 
–Drink s/foods containing quinine (eg, tonic water). 
Parti cipants will be asked to refrain fro m blo od donation from screening unt il 30 days after the 
last study  drug administrati on.
Parti cipants will be asked not to consume more than 4 servings (1 serving is app roximately  
equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated 
beverages per day  from 1 week before admission to the qualificat ion phase until after the 
follow-up visit or ET. Participants will not be permitted to co nsume caffe ine-containing 
beverages during inpat ient stays at the study  site. 
Parti cipants will be requi red to abstain from smoking or vaping for at least 2 hours before and 
8 hours after dosing on the day  of dosing in the inpati ent qualificat ion phase an d treatment 
phase sequences. Smoking or vaping will be permitted at short breaks after at least the 8 -hour 
postdose procedures, at the discret ion of the study  site staff. Parti cipants will not be permitted 
to use other nicotine -containing products (includi ng ni cotine topi cal patches, nicotine gum, or 
nicotine lozenges) during the inpat ient periods.
Parti cipants will be requi red to follow the informed consent form (ICF) and the clinic code of 
conduct.
7.6 Criteria for Discontinuation or Withdrawal of a Participa nt
A participant is free to withdraw his/her consent and discont inue participat ion in the study  at any  
time for any  reason. 
The primary  reason for di scont inuat ion or wi thdrawal  of the parti cipant from  the study  or study 
drug should be recorded in the elec troni c case report form (eCRF) using the categories listed below. 
For screen failure participants, refer to Section 9.1.14 .
Withdrawal by part icipant.
Withdrawal o f consent.
Failure to meet continuat ion criteria.
Protocol  violation:
–Noncom pliance wi th study  drug or study  schedule.
–Use of unacceptable conco mitant m edicat ion(s).
–Use of prohibited substances (positive THC UDS will be permitted at admissio n to the 
qualifi cation phase as long as the participant is not impaired at admissio n, in the clinical 
judgment of the investigator).
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 38of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL–Other major protocol vio lation.
AE.
Physician decisio n.
Pregnancy.
Study  terminated by  sponsor or study  site terminated by  sponsor.
Lost to follow-up.
Other.
The invest igator must maintain a record of all participants who discont inue from the study  before 
completion; the reason(s) for study  discont inuation will be documented. In the event that a 
participant chooses to withdraw fro m the study, the invest igator should make a reasonable attempt 
to obtain and record the reason(s) for withdrawal, if possible, although the participant is not 
obligated to provide such a reason. 
In the event that a participant is discont inued while at the study  site,the ET procedures shown in 
 shoul d be perform ed before di scharge from  the 
study  site. For any case of early discont inuat ion(whether or not the participant is at the study site), 
the invest igator should ask the participant to participate in the fo llow-up visit procedures, provided 
that the participant has not withdrawn consent for those procedures. If a participant refuses to 
complete ET and/or the follow -up procedures, this informat ion will be recorded.
7.7 Procedures for Discontinuation or Withdrawal of a Participant
The invest igator may discont inue a participant’s study participat ion at any  time during the study  
when the partici pant meets the study  discont inuat ion criteria described in Section 7.6. In addit ion, 
a participant may discont inue his or her participation without giving a reason a t any  time during 
the study . Shoul d a participant’s participat ion be discontinued, the primary  criterion for 
termination must be recorded by the investigator. In addit ion, efforts should be made to perform all 
procedures scheduled for the ET visit. 
8.0 CLINICAL STUDY MATERIAL MANAGEMENT
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling of Study Drug
In thi s protocol , the term  study  drug refers to all or any  of the drugs defined below.
Invest igational product: soticlestat 300, 600, or 900 mg orally administered via 100 mg immediate 
release tabl ets or m atching placebo.
Reference therapy : overencapsulated alprazolam 2 mg or matching placebo.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 39of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALStudy  drug will be administered in a double -blind, double -dummy manner with the oral doses of 
soticlestat or m atching pl acebo and overencapsulated alprazolam 2 mg or matching placebo 
administered at each treatment period in the treatment phase. 
The sponsor will supply study  site(s) wi th soticlestat (TAK -935) 100 m g tablets, and pl acebo for 
match 100 mg tablets. Soticlestat 300 mg tablets may be used instead of 100 mg if bioequivalence 
is demo nstrated in an ongo ing BE study TAK -935-1014.‡
Study  drug will be supplied in high -densi ty polyethylene bottl es wi th induct ion seal and 
child -resistant caps. Each bottle will contain a label that includes pert inent study informat ion and 
cauti on statem ents. For m ore inform ation on the study  drug, pl ease see the study  pharmacy 
manual.
Soticlestat clinical study  material will be labeled according to the coun try’s regu latory  
requi rements. Soticlestat and placebo will be provided in open -label configurat ion, and unblinded 
study  site staff will  prepare blinded dosing before administration to participants.
Alprazo lam 2 mg and matching placebo will be compounded and supplie d for use in this protocol. 
Instructi ons for preparation of overencapsulated alprazolam 2 mg and matching placebo can be 
found in the pharmacy manual.
8.1.2 Storage
Sponsor -supplied study drug must be kept in an appropriate, limited- access, secure place unt il itis 
dispensed or returned to the sponsor or designee for destruction. Study  drug m ust be stored under 
the condi tions specified on the label and remain in the original container unt il dispensed. A daily 
temperature l og of  the drug storage area must be maint ained every  day.
Please refer to the pharmacy manual for addit ional informat ion related to the study  drug. In 
instances where the protocol and pharmacy manual text conflict, the pharmacy manual text shall 
supersede the text in the protocol.
Site staff shou ld follow thei r internal processes for managing, storing and dispensing 
controlled- substances.
8.1.3 Dose and Regimen
Route of administration: oral.
Dose regimen: single dose, once on Day  1 of each treatm ent peri od.
Durati on of  evaluat ion and treatment: Participants who complete the study will be in the study for 
approximately  11 weeks (including approximately  5 weeks in the qualificat ion and treatment 
phases co mbined).
This study  includes: 
Screening phase of up to 4 weeks. 
                                               
‡Protocol will be updated accordingly.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 40of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALQualificat ion phase (4 day s).
Treatment phase (5 periods with 7 -day washout between each study  drug administrati on).§
Follow-up visit occurring 7 days after last treatment period and discharge from the CRU.
Table 8.adescribes the dose and tablet/capsule count that will be provided to each group.
Table 8.a Treatment Description
TreatmentSoticlestat 
(100 mg)Placebo for Soticlestat 
(100 mg) aAlprazolam b
(2 mg)Placebo for Alprazolam 
(2 mg) c
Number of Tablets/capsules
A 3 6 0 1
B 6 3 0 1
C 9 0 0 1
D 0 9 1 0
E 0 9 0 1
aPlacebo that matches 100 mg soticlestat tablets. 
bOverencapsulated alprazolam.
cPlacebo that matches overencapsulated alprazolam 2 mg. 
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by a 
study  participant, at a dose above that which is assigned to that individual part icipant according to 
the study  protocol . 
Note: Because of the double -blind nature of the study , any addi tional tablets or capsul es ingested 
at a dosing event will be considered an overdose during the period in which the study  is blinded. 
Invest igator to refer to Section 8.5for decisio ns regarding unblinding for medical treatment.
All cases of overdose (with or without associated AEs) will be documented. Cases of overdose 
without m anifested si gns or symptom s are not considered AEs. AEs associated with an overdose 
will be documented on AE eCRF(s) according to Section 10.0.
SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on10.1.4 .
In the event of drug overdose, the participant should be treated sy mptom atically.
                                               
§At minimum, there will be a 4- day washout between the qualification phase and the treatment phase.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 41of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL8.2 Study Drug Assignment and Dispensing Procedures
8.2.1 Assignment of Participant Identification Number
A unique 8- digit parti cipant i dentificat ion number (participant number) will be assigned to each 
participant at the time that informed consent is explained; this participant number will be used 
throughout the study .
8.2.2 Study Drug Assignment
Each participant will be assigned a treatment sequence in each double -blind phase 
(ie,1qualificat ion phase and 1 treatment phase), in accordance wit h the randomi zation schedule 
(refer to Section 6.1).
Refer to the study  manual  for details concerning sample tracking.
8.3 Randomization Code Creation and Storage
Randomization per sonnel of the sponsor or designee will generate the randomizat ion 
table/schedule and will provide it to the unblinded study site staff (eg, pharmacist) before the start 
of the study . All randomizat ion informat ion will be stored in a secured area, accessibl e only  by 
authori zed personnel.
The qualificat ion phase of this study will be doubl e-blind. The treatment phase of the study will be 
doubl e-blind and double dummy; the invest igator and participants are blinded to treatment 
assignment. The study  drug will b e provi ded to the site as soticlestat 100 mg tablets and matching 
placebo tablets in an unblinded manner. Blinding of treatment will be performed by the unblinded 
study  site staff.
8.4 Study Drug Blind Maintenance 
The study  drug blind is maintained through a randomizat ion schedule held by the dispensing 
pharmacist. The study  drug blind will be maintained for persons responsible for the ongoing 
conduct of the study  (monitors, invest igators, etc) and those responsible for data analysis and 
interpretati on of resu lts at the conclusio n of the study, such as bio metrics personnel. The treatment 
phase blind shall not be broken by the invest igator unless informat ion concerning the study drug is 
necessary  for the medical treatment of the participant. The sponsor or desig nee must be notified as 
soon as possible if the blind is broken.
Since the maintenance of the blind may be co mpromised because of results fro m drug 
concentrations and/or pharmacodynamics assessments, such results should not be disclo sed before 
blind breaki ng. In the event that results must be reported to the investigator before breaking the 
blind, all efforts should be made to maintain the blind (eg, as changing a medicat ion ident ificat ion 
number in order to avoid identificat ion of participants by  the labor atory  site personnel).
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 42of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL8.5 Unblinding Procedure
If the participant is found to be not eligible for the qualificat ion phase, the invest igator should 
record the primary reason for failure on the applicable eCRF.
A group of participants that start the qualificat ion phase on the same day  will be considered a 
cohort for unblinding purposes. Upon completion of each qualificat ion phase cohort, the 
rando mizat ion codes for these participants will be unblinded (site), and the eligibilit y of 
participants to parti cipate in the treatm ent phase will be assessed as described in Section 7.3.
Any other instance of unblinding should only be considered for the safet y of the parti cipant. The 
study  drug blind shall not be broken by  the invest igator unless informat ion concerning the study  
drug i s necessary  for the m edical treatment of the participant. All study  assessments and causalit y 
assessment should be performed, if possible, before unblind ing. In the event of a medical 
emergency, if possible, the medical mo nitor and the Takeda tri al clinician shoul d be contacted 
before the study  drug blind is broken to discuss the need for unblinding. If unblinding is deemed 
necessary  by the invest igator, the investigator can unblind the participant’s treatment allocat ion by 
contacting the dispensing pharmacist.
The sponsor must be notified as soon as possible if the study drug blind is broken. The date, time, 
and reason the blind is broken must be recorded in the source documents and the same informat ion 
(except the time) must be recorded on the eCRF.
If any study  site personnel  are unblinded, study  drug m ust be stopped immediately  and the 
participant m ust be wi thdrawn fro m the study . 
8.6 Accountability and Des truction of Sponsor -Supplied Drugs
Drug supplies will be counted and reconciled at the study site before being returned to the sponsor 
or desi gnee, or destroyed by the site where allowed by  institutional process and as per sponsor 
instructi ons. Any remaini ng supplies there were purchased by site will be destroyed, as appropriate, 
by the site.
The investigator or designee must ensure that the sponsor -supplied drug is used in accordance wit h 
the protocol and is dispensed only to participants enro lled in the s tudy. To document appropri ate 
use of sponsor -supplied drug (soticlestat tablets or matching placebo), the invest igator or designee 
must maintain records of all sponsor -supplied drug delivery to the study site, study site inventory, 
dispensat ion and use by each participant, and return to the sponsor or designee.
Upon receipt of sponsor -supplied drug, the invest igator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantit y is correct, and th e 
medicat ion is in good condit ion. If quant ity and condit ions are acceptable, invest igator or designee 
shoul d acknowl edge the recei pt of the shipment by si gning bottom  half of the packing list and 
emailing as per instructions provided on the form. If there are any  discrepancies between the 
packing list versus the actual product received, Takeda must be contacted to resolve the issue. The 
packing list should be filed in the invest igator’s essential document file.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 43of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALThe investigator or designee must maintain 10 0% accountabilit y for all sponsor -supplied drugs 
(soticlestat and m atching pl acebo) received and dispensed during his or her ent ire parti cipat ion in 
the study . Proper drug accountabilit y includes, but is not limited to, the fo llowing requi rements:
If any d ispensing errors or discrepancies are discovered, the sponsor must be notified 
immediately .
The invest igator or designee must record the current inventory of all sponsor -supplied drugs 
(soticlestat) on a sponsor -approved drug accountabilit y log. 
All study drug not returned to the study  site by  a parti cipant m ust be invest igated by the study 
site and appropri ately docum ented on the drug accountabilit y log.
Before study site closure or at appropriate intervals, a representative from the sponsor or its 
design ee will perform  sponsor -supplied drug accountabilit y and reconciliat ion before 
sponsor -supplied drugs are returned to the sponsor or its designee for destruction. Destruction 
may be completed by the study  site after full accountabilit y is co mpleted wi th sponsor 
preapproval. The study site must have destructi on procedures in place and be able to supply  a 
“Certificate of Destruction” or similar document. The invest igator or designee will retain a 
copy  of the documentati on regarding sponsor -supplied drug account abilit y, return, and/or 
destruction, and originals will be sent to the sponsor or designee.
The invest igator will be notified o f any expiry date or retest date extension o f sponsor -supplied 
drug during the study  conduct. On expiry date notificat ion from the sponsor or designee, the 
study  site must com plete all instructions outlined in the notificat ion, including segregation of 
expired sponsor -supplied drug for return to the sponsor or its designee for destruction.
In the event of expiry date extensio n of sponsor -supplied drug already at the study site, sponsor 
supplied drugs may  be relabeled wi th the new expiry  date at that study  site. In such cases, 
Takeda or its designee will prepare addit ional labels, certificates of analyses, and all necessar y 
docum entation for com pletion of  the procedure at the study  site.
9.0 STUDY PLAN 
9.1 Study Procedures
The fo llowing sect ions describe the study procedures and data to be collected. For each procedure, 
participants are to be assessed by the same invest igator or study site personnel whenever possible. 
9.1.1 Informed (e)Consent Procedure
Inform ed electronic or written consent ([e]consent) must be obtained before the participant enters 
into the study  and before any  protocol -directed procedures are performed.
A unique participant ident ificat ion number (participant number) will be assigned to each 
participant at the time that informed (e)cons ent is obtained; this participant number will be used 
throughout the study .
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 44of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALParti cipants consent ing via (e)consent, where available, will electronically sign consent forms 
(paper consent forms will be used instead if required by local regulat ions).
(e)cons ent provides the same informat ion as wr itten consent forms, but in an electronic format that 
may include mult imedia components. (e)consent does not replace the important discussio n 
between the participants and study  site staff or investi gator. Regardless o f the consent 
format—wri tten or (e)consent —the study  site is responsible for the consenting process. The 
requi rements of informed consent are described in Section 15.2.
9.1.2 Demographics, Medical History, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth, sex, Hispanic ethnicit y, and 
race as described by the part icipant at screening.
Medical history to be obtained will includ e determining whether the participant has any significant 
condi tions that resolved at or before signing informed consent. Ongoing condit ions are considered 
concurrent medical condit ions (see Sect ion9.1.10 ).
Any medication relevant to eligibilit y criteria and efficacy/safet y evaluation stopped at or within 6 
months before signing of informed consent will be obtained. 
9.1.3 Weight and Height
Weight and height will be meas ured while the participant is wearing indoor clothing and wit h 
shoes off. If unable to obtain height or weight, data may be co llected fro m other sources 
(eg,medical records). The invest igator must record in the source document the reason for not 
obtaining height or wei ght (eg, the parti cipant i s in a wheelchair).
The values should be reported to 1 decimal place by  rounding. 
9.1.4 Vital Sign Procedure
The fo llowing vital signs will be recorded : systolic and 
diastolic blood pressure (mm Hg), pulse rate (beats/minute), respiratory rate (breaths/minute), and 
temperature (°C or °F). If clinically significant vital sign changes f rom screening/baseline are 
noted, the changes will be documented as AEs in the AE eCRF. Screening/baseline events will be 
docum ented in the m edical history  eCRF. Clinical significance is defined as any  variation in vit al 
signs that has m edical relevance an d may resul t in an alteration in medical care. The invest igator 
will cont inue to monitor the participant until the parameter returns to baseline or until the 
investigator determines that follow -up is no l onger medically  necessary .
When vital signs are sche duled at the same t ime as blood draws, the blood draw will take priorit y 
and vital signs will be obtained wit hin 0.5 hour before or after the scheduled blood draw.
9.1.5 ECG Procedure
For each participant, 12 -lead di gital ECGs will be collected  
 Parti cipants m ust be supine for approximately 5 minutes before ECG 
collect ion and rem ain supine but awake during ECG collect ion.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 45of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALECGs m ay be obtained at addit ional times, when deemed clinically necessary. Collect ion of more 
ECGs (more replicates) than expected at a particular time po int is allowed, when needed to ensure 
high-qualit y recordings.
ECGs will init ially be interpreted by a qualified physician (the invest igator or qualified designee) 
at the study  site as soon as possible after the time of ECG collect ion, and ideally while the 
participant is st ill present at the study site, to determine whether the participant meets entry criteria 
at the relevant visit(s) and for immediate participant management, should any clinically relevant 
findings be ident ified.
After enrollment, if a clinically significant increase in the QT/corrected QT interval from baseline 
or other clinically sig nificant quantitative or qualit ative change fro m baseline is identified, the 
participant will be assessed by the investigator for symptoms (eg, palpitat ions, near syncope, 
syncope) and to determine whether the participant can cont inue in the study , and the medical 
monitor or the sponsor should be contacted. The investigator or qualified designee is responsible 
for determining if any change in part icipant’s management is needed and must document his/her 
review of the ECG printed at the time of evaluat ion fro m at least 1 of the replicate ECGs fro m each 
time point.
Any clinically  significant finding that was not present at baseline will be reported and discussed 
with the m edical m onitor or the sponsor. When there are differences in ECG interpretation 
between th e invest igator (or qualified designee) and the study  site/local cardi ologist, the 
investigator (or qualified designee’s) interpretation will be used for study  entry  and immediate 
participant management. The invest igator (or qualified designee) must documen t his/her review of 
the ECGs printed at the time of collection.
9.1.6 Physical Examination Procedure
A physical examinat ion will be performed . A full 
examinat ion will include the fo llowing assessments: ey es; ears; nose; throat; cardiovascular 
system; respiratory  system; gastrointestinal system; dermatologic system; musculo skeletal  system; 
extremit ies; nervous system; lymph nodes; and other.
If clinically  significant changes from  screening/baseline are noted, the changes will be 
docum ented as AEs in the AE eCRF. Screening/baseline events will be documented in the medica l 
history  eCRF. Clinical significance is defined as any variat ion in physical findings that has 
medical relevance and may result in an alterat ion in medical care. The invest igator will cont inue to 
monitor the parti cipant until the parameter returns to baseline or until t he invest igator determines 
that follow-up is no l onger m edically  necessary .
9.1.7 Procedures for Clinical Laboratory Samples
All samples will be collected in accordance with acceptable laboratory procedures. Details of these 
procedures and specimen handling will be given in the laboratory  manual. 
Table 9.alists the tests that will be obtained for each laboratory  specimen.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 46of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALTable 9.a Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis
Erythrocy tes
Hemoglobin
Hematocrit
Red blood cell indices
Mean corpuscular volume
Mean corpuscular hemoglobin
Mean corpuscular hemoglobin 
concentration
Red cell distribution width
White blood cell count and differential
Neutrophils, segmented
Lymphocy tes
Monocytes
Eosinophils
Basophils
Platelets
Mean platelet volumeSodium
Potassium
Total bilirubin
Direct bilirubin
Indirect bilirubin
Alkaline phosphatase
ALT
AST
Gamma glutamyl transferas e (-)
Blood urea nitrogen
Creatinine a
Urea
Calcium
Phosphate
Glucose
Albumin
Protein
Carbon dioxide
Magnesium
Chloride
Alpha 1- acid glycoprotein (baseline only) bpH
Protein
Glucose
Ketones
Bilirubin
Erythrocy tes
Leukocyte esterase
Nitrite
Urobilinogen
Calcium
Calcium/creatinine
Microscopy c
Swab test
Severe acute respiratory syndrome coronavirus 2 
Other Serum
HIV
Hepatitis B virus surface antigen
Hepatitis B core antibody
Hepatitis C virus antibody
Female participants only:
Beta human chorionic gonadotropin, for pregnancy (WOCBP only)
FSH, if menopause is suspected
Other Urine
UDS for alcohol, if available or a breath test, amphetamines, barbiturates, benzodiazepines, buprenorphineand/or 
metabolite, cannabinoids/THC, cocaine and/or metabolites, 3-methoxy-4,5 -methy lenedioxy amphetamine, 
methado neand/or metabolite, opiates, oxycodone and/or oxymorphone, phencyclidine. Note: for any UDS after taking 
the first dose of study drug exclude benzodiazepines. 
Female participants only:
Beta human chorionic gonadotropin, for pregnancy (WOCBP only)
ALT: alanine aminotransferase: AST: aspartate aminotransferase; FSH: follicle -stimulating hormone; THC: 
tetrahy drocannabinol; UDS; urine drug screen; WOCBP: women of child -bearing potential.
a Site to calculate the creatinine clearance only at screening visit for inclusion criteria.
b Collected at baseline; however, results are not required to assess participant eligibility. 
cIf urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a micros copic examination (for red blood 
cells, white blood cells, bacteria, casts, and epithelial cells) will be performed.
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 48of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALThe list of excluded medicat ions is provided in Section 7.4.
9.1.9 Documentation of Substance Use History
A history of all drugs used for recreational/nonmedicinal purposes (ie, psychoact ive effects) in the 
past 2 y ears will be co llected. History, including drug preference (ie, drug of cho ice) and 
frequency of use (ie, average number of uses per week before screening) and date/time of last use, 
will be co llected using reported drug names, by drug class (eg, cannabino ids, depressants, 
dissoci ative anesthet ics, hal lucinogens, opio ids and morphine derivat ives, stimulants). 
A history  of alco hol use (ie, average number of drinks [beer [354 mL/12 oz], wine [118 mL/4 oz], 
or distilled spirit s [29.5 mL/1 oz]] per week and number of occasio ns of binge drinking [more than 
3 drinks/5 drinks in a sitting for female/male participants]) in the 6 months before screening and 
smoking (sm oker/non -smoker, if sm oker, number of ci garettes per day ) will  also be collected.
DSM -IV-TR m odules will be included as a part of the recreational drug/alcohol  use history  and 
used to screen for alcoho l and substance dependence.
9.1.10 Documentation of Concurrent Medical Conditions
Concurrent medical condit ions are those significant ongoing condit ions or diseases that are present 
at signing of the ICF. The se include clinically significant laboratory , ECG, or phy sical 
examinat ion abnormalit ies noted at Visit 1, according to the judgment of the invest igator. The 
condi tion (ie, diagnosis) should be described and recorded in the eCRF.
9.1.11 Clinical Assessment of Suicidal Ideation and Behavior
Suicidal  ideati on and behavi or will  be assessed by  use of  the C -SSRS. The C- SSRS i s a 3-part 
scale that measures suicidal ideat ion (eg, participant endorses thoughts about a wish to be dead or 
has other thoughts of suicide), intensity of ideati on (f requency), and suicidal behavior (actually , 
interrupted, and aborted attempts at suicide) (Posner et al . 2011 ).
The versions of the C -SSRS used for all participants in this inpat ient study  will be the 
screening/baseline and Since -Last-Visit C-SSRS. When administering the screening/baseline 
versio n, both lifet ime and within the last 12 months will be assessed. 
Study  staff trained in the administration of the C -SSRS will assess participant suicidalit y using the 
C-SSRS. Ult imately, the determination o f the presence o f suicidal ideat ion or behavior depends on 
the clinical judgment of the invest igator.
If a particip ant exhibi ts signs of suicidal ideat ion or behavior as per the clinical judgement of the 
investigator, the participant will be wit hdrawn from the study as described in Sect ion
 7.7. With the 
ident ificat ion of positive symptoms of depression and suicidal ideat ion, the participant will be 
referred for professio nal psychiatric assessment and necessary fo llow-up.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 49of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL9.1.12 Contraception and Pregnancy Avoidance Procedure
9.1.12.1 Male Parti cipants and Their Female Partners
Male parti cipants who participate in the study  are not requi red to use barrier contraception. 
Donati on of  sperm  is not all owed during the study  and wi thin 90 days fo llowing the l ast 
administration of the study  drug.
9.1.12.2 Female Participants and Their Male Partners
Pregnancy testing at screening, admissio n to the qualificat ion phase (before receiving any study  
drug), admissio n to the treatment phase, and the participant’s last clinic visit will be processed 
using the local labora tory. Additional pregnancy tests (serum or urine) may  be perform ed 
throughout the study  at the invest igator’s discretion. 
Please refer to Section 7.1for inclusio n criteria for detailed contraception requirements.
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
A wo man is considered a woman of child -bearing potenti al (WOCBP), ie, fert ile, following 
menarche and unt il beco ming post- menopausal unless permanent ly sterile. Permanent sterilizat ion 
methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy . 
A postm enopausal  state is defined as no menses for 12 months without an alternat ive medical 
cause. A high f ollicle-stimulat ing horm one (FSH) level in the postmenopausal range 
(FSH >40 IU/L) may be used to confirm a postmenopausal state in younger women (eg, those <45 
years o ld) or women who are not using hormonal contraception or hormonal replacement therapy. 
However, in the absence o f 12 m onths of amenorrhea, a single FSH measurement is insufficient.
Female participants of childbearing potential must have a negat ive serum human chorionic 
gonadotropin (hCG) pregnancy  test at screening and at the end of treatment They  must have a 
negat ive urine hCG pregnancy test before dosing on Day -1 of the qualificat ion phase and on the 
day preceding each dose in the treatment phase  for subj ects who are discharged 
during washout. If urine cannot be collected at the specified visit, the reason should be documented 
in the source document. The results of the serum pregnancy test ob tained at screening must be 
confirmed to be negat ive by the invest igator before receiving study drug. During the course of the 
study , participants will receive continued guidance with respect to the avo idance o f pregnancy and 
ova donati on as part of the study  procedures (not allowed with in 32 days of the last dose). An 
additional serum  or urine hCG pregnancy  test will  be perform ed at the final visit.
9.1.12.3 Contraceptive Methods for Female Participants of Childbearing Potential
Effect ive contraceptive methods include the fo llowing:
–Doubl e-barrier method (contraceptive sponge, diaphragm, or cervical cap wit h spermicida l 
jellies or creams PLUS male condo m).
–Progestogen -only horm onal contraception, where inhibit ion of ovulation is not the primar y 
mode of act ion, PLUS condom with or without spermicid e.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 50of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALHighly effect ive contraceptive methods include the fo llowing:
–Nonhorm onal Methods:
a)IUD (intrauterine device).
b)Bilateral tubal occlusio n or bilateral tubal ligat ion or vasectomized partner (provided 
that partner is the sole sexual partner of the trial pa rticipant and that the vasectomized 
partner has received medical assessment of the surgical success).
c)Sexual abstinence: Sexual abst inence may be considered as a method only if defined as 
refraining fro m het erosexual intercourse and determined to be the us ual lifest yle before 
entering the study  with reliabilit y of abstinence for the duration of the study  
participat ion and for 32 days after last dose of study drug.
Horm onal methods:
–Combined (estrogen and progestogen) hormonal contraception associated with inhibit ion 
of ovul ation initiated at least 3 months before the first dose of study  drug OR combined 
with a barrier method (male condo m, female condom or diaphragm) if for shorter duration 
until she has been on contraceptive for 3 month s.
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation initiated 
at least 3 m onths before the first dose of study  drug OR combined with a barrier method 
(male condom , female condo m or diaphragm ) if shorter until she has been on the 
contraceptive for 3 months.
9.1.12.4 General Guidance With Respect to the Avoidance of Pregnancy
Such guidance should include a reminder of the fo llowing:
Contraceptive requirements of the study .
Assessment of participants compliance through such quest ions as:
–Have you used the con tracepti on consistent ly and correctly since the last visit ?
– H ave y ou forgotten to use contraception since the last visit ? 
–Are y our menses l ate? (Even in wo men wit h irregular or infrequent menstrual cycles, a 
pregnancy test must be performed if the answer is “yes.”)
–Is there a chance you could be pregnant ?
9.1.13 Pregnancy
If any part icipants is found to be pregnant during the study, she should be wit hdrawn immediately 
and the study drug should be immediately discont inued. In addit ion, any pregnancies in the partn er 
of a male parti cipant during the study , or f or 90 days after the last dose, should also be recorded 
following authori zation from the participant’s partner.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 51of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALIf the pregnancy  occurs during administration of active study  drug, or wi thin 90 days of the last 
dose of active study  drug, the pregnancy should be reported immediately, using a pregnancy 
notification form, to the contact listed in Section 1.1.
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the parti cipant of their right to receive treatment information. If th e parti cipant chooses to 
receive unblinded treatment informat ion, the individual blind should be broken by the invest igator. 
Parti cipants randomized to placebo need not be followed.
If the female participant and/or female partner of a male participant agre es to the primary care 
physician being informed, the investigator should notify the primary care physician that the female 
participant/female partner of the participant was participating in a clinical study  at the tim e she 
became pregnant and provide detai ls of the study  drug the partici pant received (blinded or 
unblinded, as applicable).
All pregnancies, including female partners of male participants, in participants on active study  
drug will be fo llowed up to final outcome, using the pregnancy  form. Pregn ancies will remain 
blinded to the study team. The outcome, including any premature terminat ion, must be reported to 
the sponsor. An evaluat ion after the birth of the child will also be conducted.
9.1.14 Documentation of Screen Failure
Invest igators must account f or all  parti cipants with a signed informed consent. If the participant is 
found to be ineligible for the study  before randomizati on, the invest igator should record the 
primary  reason for screen failure in the eCRF.
Parti cipants may  be rescreened after cons ultation wi th the m edical m onitor or sponsor.
The primary  reason for screen failure is recorded in the eCRF using the following categories:
Pretreatment events (PTE)/AE.
Did not m eet incl usion criteria or di d meet exclusion criteria (specify reason).
Significant protocol  deviat ion.
Lost to follow -up.
Withdrawal by part icipant.
Study  terminated by  sponsor.
Other (specify reason).
9.1.15 Documentation of Entry Into the Qualification Phase
Only participants who meet all o f the inclusio n criteria (Secti on 7.1) and none of the exclusio n 
criteria (Secti on 7.2) are eligible for ent rance into the qualification phase.
If the participant is found to be not eligible for the qualificat ion phase, the invest igator should 
record the primary reason for failure on the applicable eCRF;
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 52of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALThe primary  reason for qualification failure is recorded i n the eCRF using the following 
categori es:
PTE/AE.
Did not m eet incl usion criteria or di d meet exclusion criteria (specify reason).
Did not m eet qualificat ion criteria (specify  reason)
Significant protocol  deviat ion.
Lost to follow -up.
Withdrawal by part icipant.
Study  terminated by  sponsor.
Other (specify reason).
9.1.16 Documentation of Entry Into the Treatment Phase
Parti cipants who meet the criteria in Sect ion 7.3will be randomized to 1 of the 10 sequences in the 
treatm ent phase (Section 6.1).
If the participant is found to be not eligible for the treatment phase, the invest igator should record 
the primary  reason for failure on the applicable eCRF.
9.2 Safety Monitoring
The sponsor’s medical mo nitor and/or pharm acovigilance physician will mo nitor safet y data 
throughout the course of the study .
9.2.1 Reporting of Abnormal Liver Function Tests
If participants experience ALT or AST >3 times the ULN, fo llow-up laboratory  tests (at a 
minimum, serum alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be 
perform ed within a maximum o f 7 days and preferably wit hin 48 to 72 hours after the abnormalit y 
was noted. (Refer to Section 7.6and Section
 10.2.1 for the appropriate guidance part icipant 
discontinuat ion and on reporting AEs.)
If a participant is noted to have elevated ALT or AST >3 times the ULN on 2 consecut ive 
occasi ons, the abnorm ality shoul d be recorded as an SAE. In addit ion, eCRFs must be completed 
provi ding addit ional information on relevant recent history , risk factors, clinical signs and 
symptoms, and results of any addit ional diagnostic tests performed. The invest igator must contact 
the medical mo nitor for discussio n of the relevant participant d etails and possible alternat ive 
etiologies. The abnormalit y shoul d be recorded as an AE (please refer to Section 10.2.1 ).
If a participant is noted to have ALT or AST >3 × the ULN, and total bilirubin >2 × the ULN or 
INR >1.5, for which an alternative et iology has not been ident ified, a CRF must be co mpleted and 
transmitted with the SAE report form (as per Section 10.2.2). The invest igator must contact the 
medical mo nitor for discussio n of the relevant participant details, possible alternat ive et io
logies, 
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 54of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALparticipants who appear to have difficult y differentiat ing between bipo lar and unipo lar VAS (eg, 
making errors such as selecting 50 as neutral for a unipo lar scale) or difficult y distinguishing 
between “at this mo ment” and “n ext-day” measures during the qualificat ion phase will undergo 
additional pract ice training on the difference between the scale t ypes. Addit ional training sessio ns 
will be documented in source files.
Testing condit ions for PD assessments should remain as co nsistent as possible across the study . 
Parti cipants will be m onitored carefully to ensure that they  are com pleting the PD assessments 
appropriately; all reasonable attempts should be made to rouse participants who fall asleep during 
testing cycles.
9.4.1 Subject ive Effects VASs
All VAS will be scored on a 100 -point scale, as shown in Table 9.b. The VAS may be administered 
as bipo lar or unipo lar scales, as appropriate, and the choice is determined by the nature of the 
subjective effect being measured. When VAS are administered as bipo lar scales, the neutral po int 
equals 50 (Drug Liking, Overall Drug Liking, Take Drug Again, Alertness/Drowsiness VAS). The 
neutral  point will also be labeled with an anchor, such as “neit her like nor dislike.” When VAS are 
administered as unipolar scales, the neutral po int equals 0, and anchors will be presented using text 
such as “Not at all” (score = 0) to “Extremely” (score = 100; eg, Good, Bad, H igh, and Any E ffects 
VASs). Scales that refer specifically to drug (eg, Drug Liking, Good Effects VAS, Bad Effects 
VAS, and Any  Effects VAS) are not administered predose.
For non-commercial use only
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 57of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALParti cipants eli gible for the treatm ent phase of the study  will be randomized to receive orally 
administered treatments (1 in each of 5 treatment periods) as shown in Sect ion 6.1. The exact date 
and time of the study drug administration will be recorded in the eCRF. Participants will remain in 
the CRU for at least 24 hours after the last dose of the final period, then be discharged and 
scheduled for the follow-up procedures. After the first study treatment in the treatment phase, there 
will be a washout interval o f at least 7 days before the subsequent study  drug administration .
9.5.4 Follow -up (Final Visit or ET)
The final visit (can be a phone call) will be study  Day  37 (7 day s ±3 days fo llowing Day  1 of 
treatm ent period 5, which is the last dosing day in the study) or 7 days (±3 days) fo llowing the ET 
visit. 
For all participants receiving study drug, the investigator must complete the end of study  eCRF 
page.
10.0 ADVERSE EVENTS
10.1 Definitions
In this study, AEs refers to both PTEs and TEAEs. PTEs are AEs that started before receiving any 
study  drug. TEAEs are AEs that started after the first study  drug administration .
10.1.1 PTEs
A PTE i s defined as any  untoward m edical  occurrence in a clinical invest igation parti cipant who 
has signed informed consent to participate in a study but before administration of any study drug; it 
does not necessarily  have to have a causal relat ionship wit h study  parti cipat ion.
10.1.2 TEAEs
A TEAE is defined as any untoward medical occurrence in a clinical investigation participant who 
has been administered a drug; it does not necessarily have to have a causal relationship with this 
treatm ent.
A TEAE can therefore be any unfavorable and unintended sign (eg, a clinically significant 
abnorm al laboratory  value), symptom, or disease temporally  associated wi th the use of a drug 
whether or not it is considered related to the drug.
10.1.3 Additional Points to Consider for AEs
An untoward finding generally may:
–Indicate a new diagnosis or unexpected worsening of a pre -exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
–Necessitate therapeutic intervent ion.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 58of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL–Requi re an invasive diagnostic procedure.
–Requi re discont inuat ion or a change in dose of study  drug or a concomitant medicat ion.
–Be considered unfavorable by the invest igator for any reason.
AEs caused by a study  procedure (eg, a bruise after blood draw) should be recorded as AEs.
Diagnoses versus signs and symptoms:
–Each event sh ould be recorded to represent a single diagnosis. Accompanying signs 
(including abnormal laboratory  values or ECG findings) or symptoms should NOT be 
recorded as additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be 
recorded appropriat ely as an AE(s).
Laboratory  values and ECG findings:
–Changes in laboratory  values or ECG findings are only  considered to be AEs if they are 
judged to be clinically  significant (i e, if som e act ion or intervent ion is required, or if the 
investigator judges t he change to be beyond the range of normal physio logic fluctuati on). 
A laboratory  or ECG re -test and/or continued monitoring o f an abnormal value or finding 
are not considered an intervent ion. In addit ion, repeated or addit ional noninvasive testing 
for ver ificat ion, evaluation or monitoring of an abnormalit y is not considered an 
intervent ion.
–If abnormal laboratory values or ECG findings are the result of pathology for which there is 
an overall diagnosis (eg, increased serum creat inine in renal failure), th e diagnosis only 
shoul d be reported appropriately as an AE.
Pre-exist ing condit ions:
–Pre-existing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as AEs. However, if the 
participant experiences a worsening or complication of such a concurrent medical 
condi tion, the worsening or complication should be recorded appropriately  as an AE 
(worsening or complicat ion occurs after start of study  drug). Invest igators should ensur e 
that the event term recorded captures the change in the condit ion (eg, “worsening of…”).
–If a participant has a pre -exist ing episodic concurrent medical condit ion (eg, asthma, 
epilepsy ), any occurrence of an episode should only  be captured as an AE if th e condi tion 
beco mes more frequent, serious or severe in nature. Invest igators should ensure that the AE  
term recorded captures the change in the condit ion fro m baseline (eg “worsening of…”).
–If a participant has a degenerative concurrent medical condit ion (eg, cataracts, rheumatoid 
arthri tis), worsening of the condition should only  be recorded as an AE if occurring to a 
greater extent to that which would be expected. Investigators should ensure that the AE 
term recorded captures the change in the condit ion (eg, “worsening of…”).
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 59of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALWorsening of AEs:
–If the participant experiences a worsening or complicat ion of an AE after any  change in 
study  drug, the worsening or complicat ion shoul d be recorded as a new AE. Investigators 
shoul d ensure that the AE term recorded captures the change in the condit ion (eg, 
“worsening o f…”).
Changes in intensit y of AEs:
–If the participant experiences changes in intensit y of an AE, the event should be captured 
once wi th the m aximum  intensity recorded.
Prepl anned procedures (surgeries or intervent ions):
–Prepl anned procedures (surgeries or therapies) that were scheduled before signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is 
perform ed early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
worsening o f the condit ion should be recorded as an AE. Complicat ions result ing fro m any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
–Elect ive procedures performed where there is no change in the participa nt’s medical 
condi tion shoul d not be recorded as AEs but should be documented in the participant’s 
source documents. Complications result ing from an elect ive surgery should be reported as 
AEs.
Overdose:
–An overdose is defined as a known deliberate or accid ental  administrati on of  
investigat ional drug, to or by  a study parti cipant, at a dose above that which is assigned to 
that individual participant according to the study  protocol . Note: Because of the 
doubl e-blind nature of the study , any  addi tional tablets or capsul es ingested at a dosing 
event will be considered an overdose during the period in which the study  is blinded. 
Invest igator to refer to Section 8.5for deci sions regarding unblinding for medical 
treatm ent.All cases of overdose (with or without associated AEs) will be documented on an 
overdose page of the eCRF, in order to capture this important safet y informat ion 
consistent ly in the database. AEs associated wi th an overdose will be documented on AE 
CRF(s) according to Section 10.0.
–SAEs of overdose should be reported according to the procedure outlined in Sect ion 10.2.
–In the event of drug overdose, the participant should be treated symptomat ically.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 60of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results i n DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the participant was at risk of death at 
the time o f the event; it does not refer to an event that hypothetically  might have caused 
death if it were more severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require in tervent ion to prevent items 1 through 5 above.
May expose the parti cipant to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
10.1.5 Intensity of AEs
The different categories o f intensit y (severit y)are characterized as fo llows:
Mild: The event is transient and easily tolerated by the participant.
Moderate: The event causes the participant discomfort and interrupts the participant’s usual activities.
Severe: The event causes considerable interferen ce with the participant’s usual activities.
10.1.6 Causality of AEs
The rel ationship of each AE to study  drug(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out , although factors other than the drug, such as underlying diseases, complications, 
concomitant medications and concurrent treatments, may also be re sponsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments.
10.1.7 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as Not Related.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 61of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL10.1.8 Start Date
The start date of the AE is the date that the first signs/symptoms were noted by  the parti cipant 
and/or invest igator.
10.1.9 Stop Date
The stop date of the AE is t he date at which the participant recovered, the event resolved but wit h 
sequelae, or the participant died.
10.1.10 Frequency
Episodi c AEs (eg, vomit ing) or those which occur repeatedly over a period of consecut ive days are 
intermittent. All other events are contin uous.
10.1.11 Action Concerning Study Drug
Drug withdrawn –a study  drug i s stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  drug.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a study  drug was stopped for a reason other than the particular AE (eg, the 
study  has been terminated, the participant died, dosing wit h study  drug was already  stopped 
before the onset of the AE).
Dose interrupted –the dose was interrupted due to the particular AE.
10.1.12 Outcome
Recovered/reso lved –participant returned to first assessment status with respect to the AE.
Recovering/resolving –the intensit y is lowered by  1 or m ore stages: the diagnosis or 
sign/symptom  has alm ost disappeared; the abnormal laboratory  value improved but has not 
returned to the normal range or to baseline; the participant died from a cause other than the 
particular AE wi th the condi tion rem aining “recovering/resolving.”
Not recovered/not resolved –there is no change in the diagnosis, signs, or symptoms; the 
intensity of the di agnosis, sign/symptom , or laboratory  value on the l ast day  of the observed 
study  period is worse than when it started; is an irreversible congenital anomaly; the 
participant di edfrom another cause with the particular AE state remaining “not recovered/not 
resolved.”
Reso lved with sequelae –the participant recovered fro m an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident bu t with 
some persisting paresis).
Fatal  –the AE i s considered as the cause of death.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 62of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALUnknown –the course of the AE cannot be fo llowed up due to hospi tal change or residence 
change at the end of the participant’s part icipation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 AE Collection Period
Collect ion of AEs will co mmence fro m Visit 1. Routine collect ion of AEs will cont inue until the 
follow-up visit .
10.2.1.2 AE Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Parti cipants may  report AEs occurring at any  other time during the study .
All participants experiencing AEs, whether considered associated with the use of the study drug or 
not, m ust be m onitored until  the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to baseline or until a satisfactory  explanati on for the changes is 
observed. All AEs will be documented in the AE page of the eCRF, whether or not the invest igator 
concl udes that the event is related to the drug treatment. The following informat ion will be 
docum ented for each event:
1.Event term .
2.Start and stop date and time.
3.Frequency.
4.Intensit y.
5.Invest igator’s opinio nof the causal relat ionship between the event and administration of study 
drug(s) (related or not related).
6.Invest igator’s opinio n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
7.Action concerning study  drug.
8.Outcom e of event.
9.Seriousness.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period, it should be reported according to the 
following procedure:
A sponsor SAE form must be completed, in English, and signed by the invest igator 
immediately  or wi thin 24 hours of first onset or notification o f the event.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 63of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALRegardless of causalit y, SAEs m ust be reported to the sponsor Global Pharmacovigilance 
departm ent or desi gnee, to the attention of the contact listed in Section 1.1, within 24 hours of 
beco ming aware of the event. This will be done by transmitt ing an electronic data capture 
(EDC) SAE report. If transmissio n of an EDC SAE report is not feasible wit hin 24 hours, then 
a facsimile of the completed paper -based SAE form should be sent. If SAEs are reported via 
fax or by  email, EDC m ust be updated as soon as possible with the appropriate information.
Any SAE spontaneously reported to th e invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
10.3 Follow -up of SAEs
If informat ion not available at the time of the first report becomes available at a later date, the 
investig ator shoul d com plete a follow -up SAE form  or provi de other wri tten docum entati on and 
transmit it immediately  within 24 hours of receipt . Copi es of  any relevant data from the hospi tal 
notes (eg, ECGs, laboratory  tests, di scharge summary , postm ortem  resul ts)shoul d be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.1 Safety Reporting to Investiga tors, IRBs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators, and IRBs in 
accordance with nat ional re gulat ions in the countries where the study is conducte d. Rel ative to the 
first awareness of the event by/or further provisio n to the sponsor or sponsor’s designee, SUSARs 
will be submitted to the regulatory  authori ties as expedited report within 7 days for fatal and 
life-threatening events and 15 day s for other serious events, unless otherwise required by national 
regul ations. The sponsor will also prepare an expedited report for other safet y issues where these 
might materially alter the current benefit -risk assessment of a study drug/sponsor supplied drug or 
that woul d be sufficient to consider changes in the study  drug/sponsor -supplied drug 
administration or in the overall conduct of the trial. The study  site also will forward a copy  of all 
expedited repor ts to his or her IRB.
10.3.2 Reporting of Abnormal Liver -
Associated Test Results 
For any  parti cipant wi th ALT >3 × ULN AND total bilirubin >2 × ULN ORINR >1.5 × ULN for 
which an alternat ive et iology has not been found, report the event as an SAE, contact the me dical  
monitor and Takeda tri al clinician wi thin 24 hours, and fo llow the addi tional monitoring, 
evaluat ion, and fo llow-up recommendations in Appendix D.
11.0 STUDY- SPECIFIC COMMITTEES
No steering committee, data safety  monitoring commi ttee, or clinical endpoint committee will be 
used in this study .
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 64of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL12.0 DATA HANDLING AND RE CORDKEEPING
The full details o f procedures for data handling will be documented in the data management plan.
AEs and concurrent medical condit ions will be coded using the Medical Dict ionary for Regulatory 
Activities (MedDRA). Drugs will be coded using the WHO Drug Dict ionary.
12.1 eCRFs
Com pleted eCRFs are required for each participant who signs an ICF.
The sponsor o r its designee will supply study  site wi th access to eCRFs. The sponsor will make 
arrangements to train appropriate study  site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and ques tionable values. Queri es may  be issued by Takeda 
personnel (or designees) and will be answered by the study  site.
The principal invest igator must review the eCRFs for completeness and accuracy and must e-sign
the appropriate eCRFs as indicated. Furthermore , the invest igator must retain full responsibilit y 
for the accuracy  and authent icity of all data entered on the eCRFs .
After submissio n of the eCRFs to the sponsor, any  change to, m odificati on of , or addi tion to the 
data on eCRFs should be made by the inve stigator with use o f change and modificat ion records of 
eCRFs (data clarificat ion form) provi ded by  the sponsor. The invest igator must review the data 
clarificati on form for com pleteness and accuracy , and must si gn and date the form.
After the lock of the study  database, any  change to, m odificati on of , or addi tion to the data on the 
eCRFs should be made by the invest igator with the approval fro m the sponsor. The invest igator 
must review the data change for completeness and accuracy , and m ust si gn and date.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by the sponsor or its designee. The sponsor or its designee will be permitted to review the 
participant’s m edical  and hospi tal records pertinent to the study to ensure accuracy  of the eCRFs. 
The completed eCRFs are the sole property of the sponsor and should not be made available in any 
form to thi rd parti es, except for authorized representatives o f appropri ate governmental healt h or 
regul atory  authori ties, wi thout wri tten permissio n of the sponsor.
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing participants, medical records, temporary media such as thermal sensit ive paper, 
source worksheets, all original signed and dated informed (e)consent forms, ICFs, participant 
authori zation forms regarding the use of personal health informat ion (if separate from the ICFs), 
including consent to use digital tools and applicat ions, if applicable, electronic copy  of eCRFs, 
including the audi t trail , and detailed records of drug disposit ion to enable evaluat ions or audits 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 65of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALfrom regulatory  authori ties, the sponsor or its designees. Any  source documentati on printed on 
degradable thermal sensit ive paper should be photocopied by the study  site and filed wi th the 
original  in the participant’s chart to ensure long term legibilit y. Furthermore, International Council 
for Harm onisat ion (ICH) E6 Section 4.9.5 requires the investigator to retain essential documents 
specified in ICH E6 (Section 8) until at least 2 y ears after the last approval of a market ing 
applicat ion for a specified drug indication being investigated or, if an applicat ion is not approved, 
until at least 2 years after the invest igation is discont inued and regulatory  authori ties ar e notified. 
In addit ion, ICH E6 Secti on4.9.5 states that the study  records should be retained unt il an amount 
of time specified by applicable regulatory  requi rements or for a time specified in the study  site 
agreem ent between the invest igator and sponsor.
Refer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval fro m the sponsor before disposing of any 
such documents.
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized before unblinding of treatment 
assignments. This document will provide further details regarding the definit ion of analysis 
variables and the statist ical analysis methodology to address all s tudy objectives.
13.1.1 Analysis Sets
Qualificat ion rando mized analysis set: All participants who are randomized in the qualificat ion 
phase.
Randomized analysis set: All part icipants who are rando mized in the treatment phase.
Qualificat ion safet y analysis set: Al l participants who receive at least 1 dose of study drug (ie, 
placebo or al prazo lam) in the qualificat ion phase. All safet y evaluations in the qualificat ion 
phase will be performed using this analysis set.
Safety analysis set: All part icipants who receive at least 1 dose of study  drug in the treatm ent 
phase. All safet y evaluations in the treatment phase will be performed using this analysis set.
Com pleter analysis set: All participants in the randomized analysis set who complete all 
treatm ent peri ods of  thetreatment phase and have at least 1 response on the VAS for Drug 
Liking “at this m oment” wi thin 2 hours postdose (hence within approximately 2 hours of 
histori cal time o f first occurrence of C max[tmax] of soticlestat and alprazo lam) for each 
treatm ent. T his analysis set may be used for supportive PD analyses.
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 67of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL13.1.3.2 Primary Endpoint
The following hypotheses will be tested for the primary  PD endpoint of Drug Li king “at thi s 
moment” VAS E max.
1.Validat ion test of the sensit ivity and integri ty of the study : Does the positive control  (C) 
produce m ean responses that show greater abuse potenti al com pared wi th placebo (P)?
H0: µC- µP≤15 vs H a: µC- µP> 15
where µ Cand µ Pare the m ean Drug Li king VAS E maxfor alprazo lam and placebo, 
respectively. The margin of 15 was selected based on previous studies of this ty pe (US 
Departm ent of Healt h and Hum an Services, FDA, CDER: Statist ical review and evaluat ion 
Applicat ion Number: 215904, Statist ical Reviews, 2022). 
2.Does the test drug (T) produce mean responses that show less abuse potential co mpared to 
positive control?
H0: µC- µT≤0 vs H a: µC- µT> 0
where µ Tis mean Drug Liking VAS E maxfor soti clestat. Thi s hypothesis will be tested 
separately  for each soti clestat dose. Reject ion of each null hypothesis would suggest lower 
relative abuse potential o f soticlestat com pared wi th alprazolam . 
3.Does the test drug produce mean responses that show similar abuse potential co mpared with 
placebo ?
H0: µT- µP≥11 vs H a: µT- µP< 11
This hypothesis will be tested separately for each soticlestat dose. Reject ion of each null 
hypothesis would suggest that soticlestat does not produce an abuse -related si gnal. The margin of 
11 was selected based on Chen and Bonson (Chen and Bonson 2013 ).
All hypotheses for the primary  endpoint wi ll be tested at 1 -sided 0.05 level o f significance. The 
hypotheses will be tested sequentially in the order listed. Within the second and third hypotheses, 
testing will be ordered from low dose to high dose. No adjustments to p -values will be made. All 
hypotheses will be evaluated using no minal p -values.
Analysis of the primary endpoint will be performed on the modified completer analysis set. A 
linear mixed effects model containing treatment, period, sequence, and first -order carry over (if 
applicable) as f ixed effects, and participant as random effect, is planned to be used to evaluate the 
hypotheses for the primary  endpoint.
If the variances across treatment groups shows potent ial heterogeneit y, the m odel will be fitted to 
allow unequal variances across tr eatment groups. If non -norm ality of residuals is detected in the 
model, a pai red t-test or sign test will be used as appropriate for hy pothesis testi ng.
Carry over effects are defined as the effect of the treatment administered in the previous treatment 
period. If the carryover effect is found to be significant at a level of 0.25, then it will be included in 
the mixed -effects m odel as a fixed effect. Otherwise, carry over effect will be dropped from the 
model.
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 69of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL13.1.5 Safety Analysis
Safety analyses for the qualificat ion phase will be based on the qualificat ion safet y analysis set. 
Safety analyses for the trea tment phase will be based on the safet y analysis set.
All AEs will be coded using the MedDRA and characterized as pretreatment and 
treatm ent-emergent according to the intake of the study drugs. TEAEs will be summarized by 
treatm ent showing the number and p ercentage of parti cipants who experienced at least 1 TEAE 
and the number of TEAEs reported. A by -participant AE data list ing including reported term, 
coded term , treatm ent, severi ty, and rel ationship to treatment will be provided. TEAEs leading to 
disconti nuation and SAEs will be listed separately.
Vital signs data will be summarized by study phase and treatment and will be listed by part icipant. 
Observed values and changes fro m baseline will be presented.
Physical examinat ion abnormalit ies, ECG results, cl inical laboratory  values, and C -SSRS 
responses will be listed by  parti cipant.
13.2 Interim Analysis
No interim analysis is planned.
13.3 Determination of Sample Size
The qualificat ion phase of the study  is based on a 2 × 2 crossover design wit h oral  doses of 
alprazo lam 2 m g and m atching placebo. The treatment phase is based on a 5- treatm ent, 
10-sequence, 5 -period Williams square crossover design with treatments A, B, C, D, and E as 
defined previously. 
Approximately  140 parti cipants will be enrolled into the qualific ation phase of the study , 
rando mized equally to the 2 sequences. Approximately 65 qualified participants will be 
rando mized equally to the 10 sequences in the treatment phase, with the intent to ensure that at 
least 39 participants are in the modified co mpleter analysis set. 
Parti cipants who are randomized but who prematurely  discontinued or are eliminated from the 
modified co mpleter analysis set may be replaced to ensure that the size of the modified co mpleter 
analysis set is sufficient, sequences are app roximately balanced, and there is at least 1 participant 
per sequence. Replacement participants will be assigned to the same treatment sequence as the 
original  parti cipant.
It is estimated that, in the treatment phase, a sample size of 39 participants in t he modified 
completer analysis set will provide at least 90% power to test each hypothesis for the primary  PD 
endpo int. 
Power cal culat ions used a paired t -test and assumed a true SD of 23 points for within -participant 
differences for each planned treatmen t com parison on the Drug Liking VAS E max, a true m ean 
difference of 26 points between alprazolam 2 mg and placebo, and a true mean difference of 
0points between placebo and each dose of soticlestat. 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 70of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALThe assumpt ions on the mean and SD of the difference be tween al prazo lam and pl acebo were 
derived from published data (Chen and Bonson 2013 ; Levy -Cooperm an et al. 2016 ; Schoedel et al. 
2018a) .
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator guarantees access to source documents by the sponsor or its designee (contract 
research organizat ion) and by  the IRB.
All aspects of the study  and i ts docum entati on wi ll be parti cipant to review by the sponsor or 
sponsor’s designee, including but not limited to the invest igator’s binder, study drug, participant 
medical records, informed (e)consent documentation, documentation of participant authorizat ion 
to use personal health inform ation and review of eCRFs and associated source documents. It is 
important that the investigator and other study personnel are available during the monitoring visit s 
and that sufficient time is devoted to the process.
In case of prolonged acc ess restri ctions to external visit s (study  monitors) to a studysite due to 
COVID -19 pandemic and wherever possible by lo cal regulati ons, rem ote source data verification 
(rSDV) may  be considered for crit ical data related to participant’s safet y and any key variables to 
ensure data accuracy  and integri ty.
If rSDV i s requi red, f ull details of the process will be included in the clinical monitoring plan 
following any applicable local guidance for secure access to remote source documents and data 
securit y provi sions to protect personal data.
14.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study  parti cipants. Shoul d other unexpected ci rcumstances arise that will 
requi re deviat ion from protocol -specified procedures, the invest igator should consult with the 
sponsor or designee (and IRB, as required) to determine the appropriate course of action. There 
will be no exemptions (a prospectively approved deviat ion) from the inclusio n or exclusio n 
criteria.
The study  site shoul d docum ent all  protocol  deviatio ns in the participant’s source documents. In 
the event of a significant deviat ion, the study  site shoul d notify  the sponsor or i ts desi gnee (and 
IRB, as required). Significant deviat ions include, but are not limited to, those that invo lve fraud or 
misconduct, increase the healt h risk to the participant, or confound interpretation of primary study 
assessment. A protocol deviat ion form shoul d be com pleted by  the study  site and si gned by t he 
sponsor or designee for any  significant deviat ion from the protocol.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 71of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be parti cipant to qualit y assurance audi ts by the sponsor or designees. In 
this circumstance, the spo nsor-designated auditor will contact the study  site in advance to arrange 
an audit ing vis it. The auditor may ask to visit the facilit ies where laboratory samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the US FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency  of Japan, Center 
for Drug Evaluat ion in China). If the study site is contacted for an inspect ion by a regulatory body, 
the sponsor should be notified immediately. The investigator and study  site guarantee access for 
qualit y assura nce audi tors to all study  documents as described in Section 14.1.
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individ ual parti cipants 
(ie,participants) according to the protocol, the ethical principles that have their origin in the 
Declaration of Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each invest igator 
will conduct the study  according to applicab le local or regi onal regulatory  requi rements and align 
his or her conduct in accordance wit h the “Responsibilit ies o f the Invest igator” that are listed in 
Appendix B. The principles of Helsinki are addressed through the protocol and through 
appendices containing requirements for informed (e)consent and invest igator responsibilit ies.
15.1 IRB Approval
IRBs m ust be consti tuted according to the applicable state and federal/loca l requi rements of each 
participat ing region. The sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB. If any member of the IRB has direct 
participat ion in this study , written notificat ion reg arding his or her abst inence fro m voting must 
also be obtained. If the study  site is unwilling to provide names and tit les of all members due to 
privacy  and conflict of interest concerns should instead provide a Federal Wide Assurance 
Number or comparable number assigned by  the US Departm ent of  Heal th and Human Services 
(for studi es including Takeda Development Center Americas).
The sponsor or designee will supply relevant documents for submissio n to the respective IRB for 
the protocol’s review and approval . This protocol , the IB, the informed (e)consent form, and, if 
applicable, participant recruit ment materi als and/or advertisements and other documents required 
by all applicable laws and regulations, must be submitted to a central or local IRB for approval . 
The IRB’s written approval of the protocol and participant informed (e)consent must be obtained 
and submitted to the sponsor or designee before commencement of the study . The IRB approval 
must refer to the study by exact protocol tit le, number, and versi on date; ident ify versio ns of other 
docum ents (eg, informed (e)consent form) reviewed; and state the approval date. The sponsor will 
notify the study  site once the sponsor has confirmed the adequacy  of study  site regul atory  
docum entati on and, when applicab le, the sponsor has received permissio n from competent 
authori ty to begin the study .
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 72of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALStudy  site must adhere to all requirements stipulated by  their respect ive IRB. This may include 
notification to the IRB regarding protocol amendments, updates to the infor med (e)consent form, 
recrui tment m aterials intended for viewing by  partici pants, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB, and submissio n of the invest igator’s final status report to IRB. All IRB approvals 
and relevant documentation for these items must be provided to the sponsor or its designee.
Parti cipant incent ives should not exert undue influence for participat ion. Payments to participants 
must be approved by  the IRB and sponsor.
15.2 Participant Information, Informed (e)Consent, and Participant Authorization
Written and (e)consent documents will embody  the el ements of informed (e)consent as described 
in the Declarat ion of Helsinki and the ICH Guidelines fo r GCP and will be in accordance wit h all 
applicable laws and regulations. The informed (e)consent form, participant authorizat ion form (if 
applicable), and participant informat ion sheet (if applicable) describe the planned and permitted 
uses, transfers, an d discl osures of the participant’s personal and personal healt h informat ion for 
purposes of conduct ing the study, including the use of electronic devices and associated 
techno logies (if applicable). The informed (e)consent form and the participant informat ion sheet 
(if applicable) further explain the nature of the study, its object ives, and potential risks and benefits, 
as well as the date informed consent is given. The informed (e)consent form will detail the 
requi rements of the participant and the fact th at he or she is free to withdraw at any  time wi thout 
giving a reason and without prejudice to his or her further medical care.
The invest igator is responsible for the preparation, content, and IRB approval o f the inform ed 
(e)consent form and if applicable, the parti cipant authori zation form. The informed (e)consent 
form, parti cipant auth orization form (if applicable), and participant informat ion sheet (if 
applicable) must be approved by  both the IRB and the sponsor before use.
The informed (e)consent form, participant authori zation form (if applicable), and participant 
inform ation sheet (if applicable) must be written in a language fully co mprehensible to the 
prospective part icipant. It is the responsibilit y of the invest igator to explain the detailed elemen ts 
of the inform ed (e)consent form, participant authorizat ion form (if applicable), and participant 
inform ation sheet (if applicable) to the participant. Informat ion shoul d be given in both oral and 
written form whenever possible and in the manner deemed a ppropriate by the IRB. In the event the 
participant is not capable of rendering adequate informed (e)consent, then the participant’s legally 
acceptable representative may provide such consent for the participant in accordance wit h 
applicable laws and regul ations.
The parti cipant, or the participant’s legally acceptable representative, must be given ample 
opportunit y to: (1) inquire about details of the study and (2) decide whether or not to participate in 
the study. If the participant, or the participant’s legally acceptable representative, determines he or 
she will participate in the study , then the informed (e)consent form and participant authorizat ion 
form (if applicable) m ust be signed and dated by  the parti cipant, or the parti cipant’s legally  
acceptable representative, at the time of consent and before the participant entering into the study. 
The parti cipant or the participant’s legally  acceptable representative should be instructed to sign 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 73of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALusing their legal names, not nicknames, using a ballpoint pen wi th either blue or black ballpo int ink 
in the case of written consent. The invest igator must also sign and date the informed (e)consent 
form and parti cipant authori zation (if applicable) at the time of consent or after the receipt of 
participant si gnature ( in the case of (e)consent) and before participant entering into the study; 
however, the sponsor may  allow a designee of the investi gator to si gn to the extent permitted by  
applicable.
Once signed, the original informed (e)consent form or certified copy  (ifapplicable), parti cipant 
authori zation form (if applicable), and participant informat ion sheet (if applicable) will be 
maintained by  the study  site. The investi gator m ust docum ent the date the participant signs the 
inform ed (e)consent in the participant’s medical record. Copi es of the signed informed (e)consent 
form, the si gned partici pant authori zation form (if applicable), and participant informat ion sheet 
(if applicable) shall be provided to the participant.
All revised informed (e)consent forms must be reviewed and signed by relevant participants or the 
relevant parti cipant’s legally  acceptable representative in the same manner as the original 
inform ed (e)consent. The date the revised (e)consent was obtained should be recorded in the 
participant’s m edical record, and the parti cipant shoul d receive a copy  of the revised informed 
(e)consent form.
15.3 Participant Confidentiality
The sponsor and designees affirm and upho ld the principle of the participant’s right to protection 
against invasio n of privacy. Throug hout this study , a parti cipant’s source data will only be linked 
to the sponsor’s clinical trial database or documentation via a participant identificat ion number. As 
permitted by all applicable laws and regulat ions, limited participant attributes, such as sex, age, or 
date of birth, and participant init ials, may be used to verify  the parti cipant and accuracy  of the 
participant’s unique ident ification number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requires the invest igator to permit the monitor or the sponsor’s designee, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated audito rs, and the 
appropriate IRBs to review the participant’s original medical records (source data or documents), 
including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n and di scharge 
summaries for hospital admissions occurring du ring a parti cipant’s study  parti cipat ion, and 
autopsy  reports. Access to a participant’s original medical records requires the specific 
authori zation of the participant as part of the informed (e)consent process (see Section 9.1.1 ).
Copi es of  any parti cipant source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, parti cipant nam e, address, and other ident ifier 
fields not collected on the participant’s eCRF).
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 74of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL15.4 Clinical Trial Disclosures and Publication
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study .During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regulation. Except as otherwise allo wable in the study site agreement, any public disclo sure 
(including publicly accessible websites) related to the protocol or study  resul ts, other than study  
recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
15.4.2 Clinical Trial Registration
In order to ensure that informat ionon clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum, register all 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov and/or ot her 
publicly  accessible websites before start of study , as defined in Takeda policy/ standard . Takeda 
contact informat ion, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available fo r public viewing.
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov and/or other publicly accessible 
websites, as required by Takeda policy/ standard, applicable laws and/or regulat ions.
15.5 Insurance and Co mpensation for Injury
Each participant in the study  must be insured in accordance with the regulat ions applicable to the 
study  site where the participant is participat ing. If a local underwriter is required, then the sponsor 
or sponsor’s designee will obta in clinical study insurance against the risk o f injury to study  
participants. Refer to the study  site agreement regarding the sponsor’s policy  on parti cipant 
compensat ion and treatment for injury. If the investigator has questions regarding this po licy, he or 
she should contact the sponsor or sponsor’s designee.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 75of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL16.0 REFERENCES
Chen, L. and Bonson, K. R. 2013. An equivalence test for the comparison between a test drug and 
placebo in human abuse potential studies. J Biopharm Stat, 23(2), 294 -306.
Levy -Cooperm an, N., Schoedel, K. A., Chakraborty , B., Bl um, D. and Cheng, H. 2016. Abuse 
liabilit y assessment of eslicarbazepine acetate in healthy male and female recreational 
sedat ive users: a phase I randomized controlled trial. Epilepsy Behav, 61, 63-71.
Paul, S. M., Doherty , J. J., Robi chaud, A. J., Belfo rt, G. M., Chow, B. Y., Hammo nd, R. S., et al. 
2013. The major brain cho lesterol metabo lite 24(S) -hydroxycho lesterol  is a potent 
allosteric modulator of N- methyl -D-aspartate receptors. J Neurosci, 33(44), 17290-300.
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., et al. 2011. 
The Columbia -Suicide Severi ty Rating Scale: init ial validity and internal consistency  
findings fro m three mult isite studies wit h ado lescents and adults. Am J Psychiatry, 168(12), 
1266-77.
Schoedel, K. A., Andreas, J. O., Doty , P., Eckhardt, K. and Sellers, E. M. 2017. Randomized, 
doubl e
-blind, placebo -and active co mparator -controlled crossover study  evaluat ing the 
abuse potential of the antie pileptic drug lacosamide in healt hy recreat ional drug users. J 
Clin Psychopharmacol, 37(6), 675 -83.
Schoedel, K. A., Stockis, A. and Sellers, E. M. 2018a. Human abuse potential of brivaracetam in 
healt hy recreat ional central nervous system depressant users . Epilepsy Behav, 78, 194 -201.
Schoedel, K. A., Szeto, I., Setnik, B., Sellers, E. M., Levy -Cooperm an, N., Mills, C., et al. 2018b. 
Abuse potential assessment of cannabidio l (CBD) in recreat ional po lydrug users: a 
rando mized, double -blind, controlled trial. Epilepsy Behav, 88, 162-71.
Williams, E. J. 1949. Experimental designs balanced for the estimat ion of residual effects of 
treatm ents. Aust J Chem, 2(2), 149 -68.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 76of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIALAppendix A
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 77of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 79of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL 
 
 
  
 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 80of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 81of 89
Protocol Incorporating Amendment 1 15 March 2023
CONFIDENTIAL
For non-commercial use only
For non-commercial use only
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 84of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALAppendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are participant to ICH GCP and all the 
applicable local laws and regulat ions. The responsibilit ies imposed on investigators by  the FDA 
are summarized in the “Statement of Invest igator” (Form FDA 1572), which m ust be com pleted 
and signed before the invest igator may participate in this study.
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data g enerated.
4.Ensure that study related procedures, including study specific (non routine/non standard panel) 
screening assessments are NOT performed on potent ial participants, before the receipt of 
written approval  from relevant governing bodies/authorities.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval of the study  and any  changes by  an appropri ate IRB that conform to 21 
CFR Part 56, ICH, and local regulatory  requi rement s.
7.Ensure that the IRB will be responsible for init ial review, continuing review, and approval of 
the protocol. Promptly report to the IRB all changes in research activit y and all ant icipated 
risks to parti cipants. Make at least y early reports on the progr ess of the study  to the IRB, and 
issue a final report within 3 mo nths of study  com pletion.
8.Ensure that requi rements for informed (e)consent, as outlined in 21 CFR Part 50, ICH and loca l 
regul ations, are m et.
9.Obtain valid informed (e)consent fro m each participant who parti cipates in the study , and 
docum ent the date of (e)consent in the participant’s medical chart. Valid informed (e)consent 
is the most current version approved by the IRB. Each informed (e)consent form should 
contain a participant authorizatio n secti on that describes the uses and disclo sures of a 
participant’s personal informat ion (including personal healt h informat ion) that will take place 
in connect ion with the study . If an informed (e)consent form does not include such a 
participant authoriz ation, then the invest igator must obtain a separate participant authorizat ion 
form from each parti cipant or the participant’s legally  acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 85of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALcontact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the re ceipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 86of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALAppendix CElements of the Participant Informed (e)Consent
In seeking informed (e)consent, the following info rmation shall be provided to each participant:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the resea rch.
3.The expected duration of the participant’s participation.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of participants invo lved in the s tudy.
7.A descript ion of the participant’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the tre atment that the participant may  receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the participant and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the partici pant or to others that re asonably may be expected 
from the research. When there is no intended clinical benefit to the participant, the participant 
shoul d be made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advant ageous to the participant and their important potential risks and benefit s.
14.A statement describing the extent to which confident iality of records i dentifying the 
participant will be maintained, and a note of the possibilit y that regulatory agencies, audito r(s), 
IRB, and the monitor may inspect the records. By  signing an informed (e)consent form, the 
participant or the participant’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any medical treatments are available if injury occurs and, if so, 
what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the participan t for parti cipat ing in the study.
17.The ant icipated expenses, if any , to the parti cipant for parti cipating in the study .
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), participant’s rights, and IRB and whom  to contact i n the event of a 
research -related inj ury to the parti cipant.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the parti cipant otherwi se is ent itled, and that the participant or the 
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 87of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALparticipant’s l egally acceptable representative may discont inue participat ion at any  time 
without penal ty or loss of benefit s to whi ch the parti cipant is otherwise ent itled.
20.The consequences o f a participant’s decisio n to withdraw fro m the research and procedures for 
orderly terminat ion of part icipation by the participant.
21.A statement that the participant or the participant’s legally  acceptable representative will be 
inform ed in a t imely manner if informat ion beco mes available that may b e relevant to the 
participant’s willingness to continue participation in the study .
22.A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws require the sponsor to do so.
23.The foreseeable circumstan ces or reasons under which the participant’s participat ion in the 
study  may be terminated.
24.A participant authorizat ion (either contained wit hin the informed (e)consent form or provided 
as a separate document) describing to the participant the contemplated and permissible uses 
and disclo sures of the participant’s personal informat ion (including personal health 
inform ation) for purposes of conducting the study . The parti cipant authori zation must contain 
the following statem ents regarding the uses and disclosu res of the parti cipant’s personal 
inform ation:
a)that personal informat ion (including personal healt h information) may be processed by 
or transferred to other parties in other countries for clinical research and safet y 
reporting purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its 
affiliates, and licensing partners; (2) business partners assist ing Takeda, its affiliates, 
and licensing partners; (3) regulatory  agencies and other health authorit ies; and 
(4)IRBs;
b)it is possible that person al information (including personal healt h information) may be 
processed and transferred to countries that do not have data protection laws that offer 
participants the same level o f protection as the data protection laws wit hin this country; 
however, Takeda will make every effort to keep your personal informat ion confidential, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research datab ases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  drug(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that participants agree not to restrict the use and disclosure of their personal 
inform ation (including personal healt h informat ion) upon withdrawal fro m the study to 
the extent that the restricted use or disclosure of such informat ion may impact the 
scientific integrity of the research; and
e)that the participant’s ident ity will remain confidential in the event that study results are 
published.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 88of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIAL25.Female participants of childbearing potential (eg, nonsterilized, premenopausal female 
participants) who are sexually ac tive must use effective or highly  effect ive contraception (as 
defined in the informed consent) from the time of signing informed consent throughout the 
durati on of the study, and for 32 days fo llowing the last dose of study drug. Regular pregnanc y 
tests wi ll be performed throughout the study  for all female part icipants of childbearing 
potenti al. If a participant is found to be pregnant during study, study drug will be discont inued.
26.Male partners of female participants must use effective or highly  effect ive contracepti on (as 
defined in the informed consent) if required as part of the method (eg, double -barrier, 
vasectomized partner) from signing the informed consent throughout the duration of the study, 
and for a minimum o f 32 day s following the l ast dose of study  drug.
For non-commercial use only
Soticlestat
Study No. TAK -935-1012 Page 89of 89
Protocol Incorporating Amendment 1 15March 2023
CONFIDENTIALAppendix DTrial Management During COVID -19 Pandemic
The purpose of this section is to safeguard the safety  of study  parti cipants, ensure continuation of 
study  conduct and uninterrupted maintenance of treatment, and preserve the integrit y of the study, 
in case o f a general public healt h crisis or pandemic, such as COVID -19. Thi s secti on addresses 
situations in which scheduled in -person clinic visit s are not feasible due to local, regional or 
national restrict ions.
The principal invest igator holds the ult imate responsibilit y for the safet y and well -being of study  
participants and shall maintain co mpliance wit h the current local and healt h authorit y guidelines 
and reco mmendat ions pertaining to the pandemic. The study  procedures outlined in this protocol 
may be modified subsequently according to any  emerging or revi sed healt h authorit y guidelines 
during conduct of the trial due to the ongoing COVID- 19 pandemic. These modified study  
procedures are to be used only during th e COVID -19 pandemic.
Due to the COVID -19 pandemic, study participants may not be able to attend scheduled in -person 
clinic visits as per protocol. The study site should follow local and country health and government 
authori ties’ restri ctions and recommenda tions on conduct of clinical trials during the pandemic.
COVID -19 vaccinat ion of participants is allowed during the study .
Any protocol deviat ions, missing visit s, or missing assessments related to COVID -19 restrict ions 
will be recorded and reported in the CSR.
For non-commercial use only
For non-commercial use only